View
361
Download
5
Embed Size (px)
Citation preview
C O M P L E M E N T O S C O N M E D I C A M E N T O S E U R O L I F E
F E L I P E T O R R E S M D .M . R . F . , T e r a p i a C e l u l a r
F E L I P E T O R R E S M D .M . R . F . , T e r a p i a C e l u l a r
E L D O L O R
R . P . M
M E D I C A M EN T O S
C O M P L E ME N T O S
E l d o l o r e s u n a s e n s a c i ó n s u b j e t i v a , p o l i m o r f a y m u l t i d i m e n s i o n a l . D i f í c i l d e c u a n t i f i c a r.
I N T R O D U C C IÓ N
S E N S A C I Ó N S U B J E T I V A :
M e z c l a l a p e r c e p c i ó n y l a e s t r u c t u r a p s i c o l ó g i c a d e l s u j e t o .
I N T R O D U C C IÓ N
I N T R O D U C C IÓ N
L a n o c i c e p c i ó nc o m p r e n d e d o s e t a p a s :
1 - L a t r a n s d u c c i ó n d e l e s t í m u l o n o c i v o p o r l a s t e r m i n a c i o n e s n e r v i o s a s p e r i f é r i c a s
2 - L a t r a n s m i s i ó n d e e s a s s e ñ a l e s h a c i a e l s i s t e m a n e r v i o s o c e n t r a l .
E l im p u l s o n o c i c e p t i v os e m o d u l a e n c a d a n i v e l d e l a v í a s e n s i t i v a
F I S I O L O G Í A D E L D O L O R
D I F E R E N T E S T IP O SD E D O L O R :
- A G U D O : S ea c o m p a ñ a d er e a c c i o n e ss o m a t o e g e t a t i v a s yd e a n s i e d a d .
- C R O N I C O ( m á s d e 6m e s e s ) : S e a c o m p a ñ ad e t e n d e n c i a sd e p r e s i v a s ,i r r i t a b i l i d a d ,t r a s t o r n o s d e l s u e ñ o ,d e l a p e t i t o y d e l a
I N T R O D U C C IÓ N
L o s d o l o r e s s o n c l a s i f i c a d o s , d e a c u e r d o c o n s u o r i g e n , e n :
C A R A C T E R Í S T I C A S D E L D O L O R
S O M ÁT I C O S
V I S C E R A L E S
N E U R Ó G E N O
C u a n d o l a s e n s a c i ó n d o l o r o s a s ep r o d u c e a n i v e l d e l a p i e l , d e la p a r a t o l o c o m o t o r o d e l t e j i d oc o n e c t i v o , s e h a b l a d e d o l o rs o m át i c o .
Pue d e a d o p t a r 2 f o r m a s :
• D o l o r s u p e r f i c i a l : c u a n d o e le s t í m u l o s e l o c a l i z a a n i v e l d e l ap i e l
• D o l o r p r o f u n d o : e l q u e s e p r o d u c ea n i v e l m u s c u l a r, ó s e o o d e l t e j i d oc o n j u n t i v o
S O M ÁT I C O S
C A R A C T E R Í S T I C A S D E L D O L O R
E l d o l o r su p e r f i c i a l , q u e s e p r o d u c ep o r e j e m p l o l u e g o d e u n p i n c h a z o ,s e c o m p o n e d e 2 p a r t e s :
- E l p r i m e r d o l o r s u p e r f i c i a l t i e n eu n c a rá c t e r a g u d o , e s b i e nl o c a l i z a d o y d e s a p a r e c erá p i d a m e n t e l u e g o d e f r e n a d o e le s t í m u l o . E s t e e s t í m u l o d o l o r o s os u e l e a c o m p a ñ a r s e d e r e a c c i o n e srá p i d a s d e h u i d a , c o m o e l r e t i r a r e lp i e a l p i s a r u n p e d a z o d e v i d r i o , af i n d e e v i t a r m á s d a ñ o s a l
S O M ÁT I C O S
C A R A C T E R Í S T I C A S D E L D O L O R
- A e s t e d o l o r s u p e r f i c i a l p r i m a r i ol e s i g u e a m e n u d o u n d o l o rs u p e r f i c i a l s e c u n d a r i o , qu e e ng e n e r a l e s d e c a rá c t e r s o r d o ou r e n t e , q u e e s m á s d i f í c i l d el o c a l i z a r y qu e d e s a p a r e c e m á sl e n t a m e n t e . E s t e d o l o r s u p e r f i c i a ls e c u n d a r i o e s n e u r o l ó g i c a m e n t ei d é n t i c o a l d o l o r p r o f u n d o , q u eo r i g i n a , p o r e j e m p l o l a c e f a l e a -u n a d e l a s f o r m a s d e d o l o r m á sc o m ú n q u e a f e c t a a l o s s e r e sh u m a n o s .
S O M ÁT I C O S
C A R A C T E R Í S T I C A S D E L D O L O R
E l c o n t r a p u e s t o a l d o l o r s o m át i c o e se l d o l o r v i s c e r a l .
E s s e m e j a n t e a u n d o l o r d e c a rá c t e rs o r d o y, j u n t o c o n l a s r e a c c i o n e s d et i p o v e g e t a t i v o , a l d o l o r p r o f u n d o .A p a r e c e p o r f r e n t e a l a d i l a t a c i ó n ol o s e s p a s m o s (e n e l d o l o r m e n s t r u a l )d e l a m u s c u l a t u r a l i s a , e n l a sh e m o r r a g i a s y e n l o s p r o c e s o si n f l a m a t o r i o s .
S e p u e d e p r e s e n t a r c o m o d o l o rd u r a d e r o c o m o e n l o s d o l o r e se s t o m a c a l e s o d e t i p o p e r i ó d i c o
V I S C E R A L E S
C A R A C T E R Í S T I C A S D E L D O L O R
J u n t o a l d o l o r s o m á t i c o y a l v i s c e r a ls e p u e d e p r e s e n t a r f i n a l m e n t e e ld o l o r n e u r ó g e n o .
S e o r i g i n a p o r e l e s t í m u l o d e f i b r a sn e r v i o s a s , c u a n d o l a s m i s m a s s o nd a ñ a d a s o i n t e r r u m p i d a s ,p r e s e n t a n d o u n c a r ác t e r a g u d o .
E j e m p l o s d e e s t e t i p o d e d o l o r e s l an e u r a l g i a d e l t r i g é m i n o y e l d o l o rf a n t a s m a l u e g o d e a m p u t a c i o n e s : e li n d i v i d u o a f e c t a d o r e f i e r e d o l o r d e lm i e m b r o a m p u t a d o . E l e s t í m u l od o l o r o s o s e o r i g i n a a n i v e l d e l m u ñ ó n
N E U R Ó G E N O
C A R A C T E R Í S T I C A S D E L D O L O R
A d e m ás d e s u o r i g e n e l d o l o r p u e d e d i f e r e n c i a r s e d e a c u e r d o c o n s u
d u r a c i ó n :
C A R A C T E R Í S T I C A S D E L D O L O R
A G U D O
C R Ó N I C O
El d o l o r agu d o t i e n e u n t i e m p ol i m i t a d o , d e s a p a r e c i e n d orá p i d a m e n t e . E s t e d o l o r p u e d et o l e r a r s e i n c l u s o s i n m e d i c a m e n t o sc o m o e n l o s t r a t a m i e n t o so d o n t o l ó g i c o s .
A G U D O
C A R A C T E R Í S T I C A S D E L D O L O R
El d o l o r c r ó n i c o p u e d e p r e s e n t a r s ec o m o d u r a d e r o e n e l d o l o r l u m b a r ot u m o r a l o r e c u r r e n t e c o m o e n l a sc e f a l e a s o a n g i n a d e p e c h o ) . L o sd o l o r e s c r ó n i c o s s o n e n g e n e r a ld i f í c i l e s d e t o l e r a r.
C R Ó N I C O
N o t o d o s l o s d o l o r e s t i e n e n s u o r i g e n e n l o s r e c e p t o r e s d o l o r o s o s :
C A R A C T E R Í S T I C A S D E L D O L O R
PS I C Ó G E N O
A v e c e s p u e d e p r e v a l e c e r u n aa f e c c i ó n p s i c o l ó g i c a , e n l a c u a l e lp a c i e n t e n o p u e d e m a n i f e s t a r s u sc o n f l i c t o s d e o t r a m a n e r a q u er e f i r i e n d o d o l o r e s .
L a a f e c c i ó n p s i c o l ó g i c a p u e d ep r e s e n t a r s e b a j o u n a f o r m as o m át i c a , c o m o u n d o l o r.
PS I C Ó G E N O
C A R A C T E R Í S T I C A S D E L D O L O R
I N T R O D U C C I Ó N
MECANISMOS PERIFERICOS: SENSIBIL IDAD PUNTUAL DE L A PIEL
E l exá m e n d e l a s e n s i b i l i d a d d e l ap i e l a e s t í m u l o s m u y l o c a l i z a d o sp e r m i t e o b s e r v a r q u e l a s e n s i b i l i d a dv a r í a d e u n p u n t o a o t r o ; m u y b a j a e na l g u n o s p u n t o s y m u y e l e v a d a e no t r o s .
T a m b i é n s e h a p o d i d o e s t a b l e c e l ae x i s t e n c i a d e p u n t o s c u t án e o s q u er e s p o n d e n a l t a c t o , a l f r í o , a l c a l o r ya a l d o l o r.
Pa r a c a d a t i p o d e s e n s a c i ó n s e h a nd i b u j a d o m a p a s p a r a c a d a r e g i ó n
INTERVENCIONES TERAPÉUTICAS: NIVEL PERIFÉRICO
E n c a d e n a m i e n t o n e u r o n a l r e s p o n s a b l e d e l a t r a n s m i s i ó n d e l a i n f o r m a c i ó n a l o s c e n t r o s
I N T R O D U C C I Ó N
E x i s t e n u n a c a t e g o r í a d e r e c e p t o r e sq u e n o p u e d e n s e r e s t i m u l a d o s m á sq u e p o r e s t í m ulo s i n t e n s o s d e o r i g e nd i v e r s o s . E s t a s e s t i m u l a c i o n e sp u e d e n s e r r e a l i z a d a s e n t r e sc o n d i c i o n e s :
1 - L e s i ó n t i s u l a r o r i g i n a d a p o rp u n c i ó n , p r e s i ó n , r o t u r a oqu e m a d u r a .
2 - I n f l a m a c i ó n t i s u l a r c o n s e c u e n t ed e l a s a n t e r i o r e s o d i r e c t a m e n t ep r o v o c a d a p o r a g e n t e s q u í m i c o se xó g e n o s o e n d ó g e n o s .
N O C I C E PT O R E S
N O C I C E PT O R E S
A p e s a r d e l a d i v e r s i d a d d e l o se s t í m u l o s , e s p o s i b l e h a b l a r d en o c i c e p t o r e s d e l a n t e d e l o s c r i t e r i o ss i g u i e n t e s (definidos por Iggo):
U mb r a l a e s t í m u l o s e l e v a d o : e s t o s ea p l i c a , s o b r e t o d o , an o c i c e p t o r e s m e c á n i c o s o t é r m i c o sc u y o u m b r a l e l e v a d oc o n t r a s t a c o n e l u m b r a l b a j o d e l o sm e c a n o o d e l o st e r m o r e c e p t o r e s e s p e c í f i c o s .
Pequ eñ a su p e r f i c i e d e l c a m p or e c e p t o r.
D e s c a r g a d e t i p o t ó n i c o , p o c oa d a p t a b l e , p e r s i s t e n t e d e s p u é sd e la p a r a d a d e l e s t í m u l o .
I n e r v a c i ó n p o r f ib r a s d e p e qu eñ od i ám e t r o (A d e l t a y C ).
A R E A IN F L A M A D A
S U S T A N C I A S A L G O G E N A S
KININAS: S o n u n g r u p o d e s u s t a n c i a sq u e t a m b i é n a c t ú a n c o m om e d i a d o r e s d e la in f l a m a c i ó n :
- BRADIKININA: S e l i b e r a e n l a sq u e m a d u r a s c u tá n e a s . L ai n y e c c i ó n l o c a l e n e l h o m b r ep r o v o c a d o l o r p o r a d e s c a r g a d el a s f i b r a s C .
- PROSTAGANDINAS: L a P G E l y PG E 2 ,i n t e r v i e n e n d e m a n e r a e v i d e n t ee n l a i n f l a m a c i ó n . L a sp e r f u s i o n e s s u b c u tá n e a s d e PG E 1a m u y b a j a s c o n c e n t r a c i o n e s e ne l h o m b r e p r o d u c e n
M A G N E T O T ER A PI A
IM A N E S T E R A PE U T I C O S
NIVEL PERIFERICO: Co n n ut r i e n t e s :
- N u t r i e n t e s qu e i n h i b e n l a s c i t o qu i n a s , p r o s t a g l a n d i n a s y l e u c o t r i e n o s .
- N u t r i e n t e s qu e i n t e r v i e n e n e n l a r e p a r a c i ó n d e l o s t e j i d o s d a ñ a d o sp o r l a i n f l a m a c i ó n .
- N u t r i e n t e s d e a p o y o a n t i o xi d a n t e .
I N T E R V E N C I O N E S T E R A PÉU T I C A S
S i g u i e n d o l a r e a c c i ó n d e B y s t a n d e r
I N T E R V E N C I O N E S T E R A PÉU T I C A SN I V E L PE R I F E R I C O : C o n C o m p l e j o s Ho m e o p át i c o s :
InmunologiaInmunologia
L a inflamación periférica es regulada por el S .N .C .
L a a f i n i d a d d e l T C R , p o r lo s c o m p l e jo s p e p t íd i c o s a s o c i a d o s a l
M H C , a u m e n t a e n la m e d i d a e n qu e lo s c o n t a c t o s s e a n m a s
r e p e t i t i v o s .
InmunologiaInmunologia
E l in t e r f e r o n ( I F N ) s e g a m a o b e t a s e p r o d u c e n b ás i c a m e n t e p o r e l e s t i m u l o d e a n t i g e n o s
v i r a l e s .
E l M A L T s e c r e t a
T G F b e t a -1 , qu e
in d u c e la p r o d u c c i ó
n le l i n f o c i t o B
e Ig A .
E l T N F - a l f a y la IL - 1 e s
e s t i m u l a d o s p o r
l i p o p o l i s a c ar i d o s
b a c t e r i a n o s y e n m e n o r
e s t ím u l o s a n t i g e n o s
v i r a l e s .
InmunologiaInmunologia
S e p u e d e s u f r i r e l s ín d r o m e d e l a s m u c o s a s p a r c i a l o
t o t a l m e n t e , s e g ún e l n u m e r o d e m u c o s a s
c o m p r o m e t i d a s .
InmunologiaInmunologia
E l M A L T , s e c o n s i d e r a u n
ór g a n o l i n f o i d e e n t r e la s
m u c o s a s , e n la s qu e in t e r v i e n e n
la s m u c o s a s r e s p i r a t o r i a s y
d i g e s t i v a s , e l T G U c o m p a r t e d r e n a je y la p r e s e n c i a d e
t e ji d o l i n f o i d e s i m i l a r a l in t e s t i n a l .
E l f e n óm e n o d e H o m i n g d e lo s
l e u c o c i t o s , o v o l v e r a l s i t i o
d e s e n s i b i l i z a c i ón
a n t i g én i c a , e x p l i c a la
m a n i f e s t a c i ón f i s i o p a t o l o g i c a
d e l s ín d r o m e d e la s m u c o s a s
InmunologiaInmunologia
P s i c o n e u r o e n d o c r i n o i n m u n o l o gia : in t e r a c c i ón e n t r e lo s
s i s t e m a s n e u r o e n d o c r i n o e in m u n e , a s í c o m o e l e s t u d i o d e lo s c a m b i o s c o n d u c t u a l e s qu e
d i c h a in t e r a c c i ón p r o d u c e .
L a in t e r a c c i ón e s b i d i r e c c i o n a l
InmunologiaInmunologia
I n f l u y e la m e n t e e n la s u s c e p t i b i l i
d a d d e e n f e r m a r , o
e n la f a c i l i d a d
p a r a r e c u p e r a r s e
d e u n a e n f e r m e d a
d ?
E l c e r e b r o y l a
r e s p u e s t a i n m u n e
E l c e r e b r o y l a
r e s p u e s t a i n m u n e
L e s i o n e s d e l h i p o t ál a m o ,
s i s t e m a l i m b i c o , o f o r m a c i ón
r e t i c u l a r
L e s i o n e s d e l h i p o t ál a m o ,
s i s t e m a l i m b i c o , o f o r m a c i ón
r e t i c u l a r
L a t e r a l i z a c i ón h e m i s f ér i c a d e la
r e s p u e s t a in m u n e
L a t e r a l i z a c i ón h e m i s f ér i c a d e la
r e s p u e s t a in m u n e
Sustento inmunológicoSustento inmunológico
Sustento inmunológicoSustento inmunológico
Clonación en ganglios linfáticos.
Son atraídos por quimiotaxis o por organotropismo o histotropismo.
NeuroendocrinoinmunologiaNeuroendocrinoinmunologiaES EL CAMPO CIENTÍFICO INTERDISCIPLINARIO QUE INVESTIGA LAS RELACIONES ENTRE EL CEREBRO ( MENTE-CONDUCTA) Y EL SISTEMA INMUNE Y SUS CONSECUENCIAS CLINICAS
NeuroendocrinoinmunologiaNeuroendocrinoinmunologia
NeuroendocrinoinmunologiaNeuroendocrinoinmunologia
NeuroendocrinoinmunologiaNeuroendocrinoinmunologia
This material is based on the presenter’s studies in PHYSIOLOGICAL REGULATING MEDICINE.
The information presented here is not to be considered a prescription and we do not accept medical or legal responsibility for misuse of the information presented. This information is for educational purposes for licensed health care professionals within their scope of practice.
43© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
1 . L O W D O S E S .K.A . - P R I N C I P L E S O F HO M E O P A T HY
1 . N E W C HE M I C A L S WIT H S .K.A . T E C HO N O L O G Y
1 . C YT O KI N E S : IT S R E L E VA N C E IN P A I N A N D IN F L A M M A T I O N
1 . E XP E R I M E N T A L D A T A T O VA L I D A T E C YT O KI N E P O T E N C Y IN A N I M A L M O D E L
1 . C L I N I C A L A P P L I C A T I O N O F L O W D O S E S .K.A . IN P A I N
What You Will L earn T oday
WE S T E RN
C O N VE NT I O N A L M E D I C I
N E
C O M P L E ME N T A R Y
A L T E R N A TIVE
M E D I C I N E
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e
P R M
45© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
Homeopathic S cience M olecular Biology
M I N E R A L ,P L A N T ,
A N I M A L D E R I VA T I VE
S
N E U R O P E PT I D E S ,
C YT O KI N E S , HO R M O N E S ,
G R O WT H F A C T O R S
P R M D R U G SA new pharmacological concept: one biotherapeutic medicine blending synergistic ingredients from Complementary Alternative Medicine and Conventional Medicine to achieve a positive clinical outcome.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
PHY SI OL OG I CA L REG U L A TI NG MEDICI NE (PRM)
T he science of P R M integrates state of the art scientific advances in:
• Homeopathy• Homotoxicology• P sycho N euro E ndocrine Immunology (P N E I )• N utritional and P hyto- M edicineTo formulate biotherapeutic medicines achieving the best individualized prescription for patients to promote recovery from illness and restoration of health
P .N .E .I .
M o l ec u l a r Bio l o
g yN u t r it i o n a l M e d ic i n e
H o m eo p a t h
yH o m o t ox i c o l o g y
Qu a nt u m P h y s
ic s
©
Dip
ar
tim
en
to
S
cie
nt
ific
o
Gu
na
S
.p.a
.
PNEI
C E N T R A L N E R VO U S
S YS T E M&
N E U R O VE G E T A T IVE S YS T E M S
IM M U N E S YS T E M
E N D O C R I N E S YS T E M
Homeostatic control systems
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A d e r , R . , P s y c h o n e u r o i m m u n o l o g y , IV e d i t i o n , v o l . 1 e 2 , A c a d e m i c P r e s s , A m s t e r d a m 2 0 0 7. I t is th e c l a s s i c a l t e x t o n t h e m a t t e r , p u b b l i s h e d fo r
D a : P s i c o N e u r o E n d o c r i n o I m m u n o l o g i a . F r a n c e s c o Bo t t a c c i o l i – R E D E d i z i o n i
T h e h o r m o n e s in f l u e n c e c y t o k i n e s l e v e l s a n d r e a l i z e a c o n n e c t i o n b e t w e e n e n d o c r i n e s y s t e m a n d im m u n e s y s t e m◦ F E M A L E S E XU A L H O R M O N E S
i n h i b i t t h e T h 2 r e a c t i o n a n d s t i m u l a t e T h 1 c y t o k i n e s
◦ C O R T I S O L in h i b i t t h e T h 1 r e a c t i o n a n d i n p a r t i c u l a r I L -2 . In t u r n , d i f f e r e n t i n t e r l e u k i n s , a m o n g w h i c h I L -
◦ I L - 1 , T N F - α, I F N - γa n d in p a r t i c u l a r I L -6 h a v e a f u n d a m e n t a l r o l e in t h e t h y r o i d f u n c t i o n : t h e y in h i b i t t h e io d i d e u p t a k e o r g a n i f i c a t i o n , t h e y h i n d e r t h y r e o c y t e s g r o w t h , t h y r e o g l o b u l i n s y n t h e s i s a n d t h e r e l e a s e o f t h y r o i d h o r m o n e s , h e p a t i c d e i o n i z a t i o n w h i c h in t u r n a c t i v a t e s T 4 t o T 3
◦ I L - 1 β a n d T N F - αi n h i b i t T R H ,
P
N
E
I
PNEI
P S Y C HE
S O MA
P S Y C HE
P. N. E. I. NETWORK AND MES S ENG ER MOLECULES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
I N T E R L E U K IN S
H O R M O N ES
N E U R O P E P T ID E S
H O R M O N ES
M e s s e n g e r M o l e c u l e s
T h e F o u n d a t i o n f o r P R MC O M M UN I C AT I N G
M O L E C UL E S a r e m e s s e n g e r s , t h e wo r d s
u s e d b y t h e 3 h o m e o s t a t i c c o n t r o l
s y s t e m s t o s p e a k e a c h o t h e r … a n d t o
u n d e r s t a n d e a c h o t h e r .© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
53
EVERY D IS EAS E IS THE
EXPRES S ION, THE CONS EQUENCE
OF CHANG ED CONCENTRATION
OF MES S ENG ER MOLECULES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
54
P. N. E. I. NETWORK AND MES S ENG ER MOLECULES
P
N
E
I
PNEI
P S YC HE
S O MA
P S YC HE
M O S C HU SN U X VO M I C A
N E U R O P E P T I D E S
HO R M O N E S
IN T E R L E U KI N S
THE P. N. E. I. NETWORK
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P
N
E
I
PNEI
P S YC HE
S O MA
P S YC HE
THE P. N. E. I. NETWORK
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
IN T E R L E UKIN S
HO R M O N ES
N E U R O P E P TID E S
HO R M O N ES
H E A L T H
P HYS I O L O G I C A L C O N C E N T R A T I O N
D I S E A S E
D I S E A S EHYP O - C O N C E N T R A T I O N
HYP E R - C O N C E N T R A T I O N1 0- 6
1 0-1 5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
4C – X6
g (gr a m )= 1
10 -1 = 0.1
10 -2 = 0.01
m g (m i lli gr a m )= 10 -3 = 0.001
μg (m i c r o gr a m )= 10 -6 = 0.000001
n g (n a n o gr a m )= 10 -9 = 0.000000001
p c g (p i c o gr a m )= 10 -12 = 0. 000000000001
f g (f e n t o gr a m )= 10 -15 = 0. 000000000000001
D E F I N I T I O N S
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e
P R MP R M c o d i f i e s t h e v i s i o n
o f t h e p h y s i o l o g i c m i l i e u o f t h e o r g a n i s m
a s a p s y c h o - n e u r o -e n d o c r i n e - i m m u n e
N E T W O R K r e g u l a t e d b y m e c h a n i s m s o f F I N E C O N T R O L ( s e n s i t i v e l i g a n d -r e c e p t o r c o n t r o l
m e c h a n i s m s )© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
59
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e :
… a d y n a m i c n e w c o n c e p t
P R M m o v e s f r o m c l a s s i c a l Ho m e o p a t h y t o
t h e r e v o l u t i o n a r y t h e r a p e u t i c c o n c e p t o f
r e s t o r i n g p h y s i o l o g y t h r o u g h a d m i n i s t r a t i o n
o f c o m m u n i c a t i n g m o l e c u l e s - h o r m o n e s ,
i n t e r l e u ki n s , n e u r o p e p t i d e s a n d
g r o wt h f a c t o r s -p r e p a r e d i n
6 0© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e
P R MT h e h o m e o p a t h i c
p r e p a r a t i o n m e t h o d o f “d i l u t i o n - d y n a m i za t i o n ”
m a ke s t h e s e c o m m u n i c a t i n g
m o l e c u l e s e v e n m o r e e f f e c t i v e .
6 1© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
6 2
TM
10 -3
1 0- 6
1 0-1 5
M I N I M A L E F F E C T I VE P HA R M A C O L O G I C A L D O S E
T O XI C CO N CE N T R A T I O
Nm g / m lP H A R M A CO L O G I CA L
CO N CE N T R A T I O Nm c g / m l
P HYS I O L O G I C A L C O N C E N T R A T I O N
ng- pcg/ml
T O XI C E F F E CT
S I D E E F F E CT S
WIT HO U T D YN A M I ZA T
IO N : N O BIO L O G I C A
LO r
P HYS I O L O G IC A L
E F F E C T S
P H A R M A CO L OG I CA L E F F E CT S
WIT H D YN A M I ZA T
IO N : P HYS I O L O G I
C A L E F F E C T S
E F F E C T S O F D I F F E R E N T D O S E S O F C YT O KI N E S
M I N I M A L E F F E C T I VE P HYS I O L O G I C A L D O S E
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
DYN AM I ZAT I O N =S.K .A.
S. Se qu e n t i a l
K . K i n e t i c
A. Ac t i v a t i o n© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
• Hypothalamus–S o m a t o s t a t i n e–Be t a -
E n d o r p h i n• Hypophysis
–F S H–L H–A CT H–P r o l a c t i n–T S H
• P ineal G land–M e l a t o n i n
• T hyroid–T S H–T r i i o d o h y r o
n i n e ( T 3 )–T h y r o x i n e
( T 4)–Ca l c i t o n i n
• P arathyroids–P a r a t h o r m o
n e ( P T H )• O vary
–Be t a -E s t r a d i o l
–P r o g e s t e r o ne
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Neuropeptides of PRM• H y I p o t h a l a m u s e
H y p o p h y s i s– Be t a - E n d o r f i n
• N u c l e u s o f r a f e o f B u l b o , o f B r i d g e a n d o f M e s e n c e f a l o . S t o m a c h a n d b o w e l– S e r o t o n i n
• P i n e a l G l a n d– M e l a t o n i n
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
6 66 6
E ffects of different doses of I L -1 - β on isolated human fibroblasts
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
in c o o p e r a t i o n wit h:
6 8© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
E xpression of N F Kb and c- fos on isolated
fibroblasts
c - f o s
1 h 1 8h
lp s a c d b
1 h
n f k blp s a c
1 8h
lp s a c d b lp s a c d b
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
E xpression of N F Kb and c-fos on isolated fibroblasts
Legend
• lps=control• A =placebo (water and alcohol)• B=pharmacological concentration• C =4C H diluted and dynamized• D =4C H only diluted but not dynamized
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
7171
T h1 T h2
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T HE IM M U N E S YS T E M
7272
T h- 1 /T h- 2 BA L A N C E
I L - 4IL - 5
C rohn’sP soriasis
A sthmaA topy
I L - 1 2IF N - T h- 1
T h- 2
T h- 2
T h- 1
I L - 1 2IF N -
I L - 4IL - 5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Th2
Th1
…in A llergy
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T h0
T h2
T h1
IN F - γ, I L -1 2
I L - 4
IN H I BI TS
S T I M U LA T E S
S T I M U LA T E S
IN H I BI TS
I L -1 2
IN F- γ
THE CONCEPT OF BALANCED eveloping Th subsets results in cross -regulation. While I L - 4stimulates Th2 differentiation and inhibits diffentiation of Th 1cells, I L - 1 2 and I F N - γ stimulates Th 1 differentiation andinhibits the development of T h2 cells.
Cooke , A. Th17 in Inflammatory Conditions. 2006, Rev Diabetic Stud 3: 72-7- Bettelli E. et al. Th17: The third member of the effector T cell trilogy. Current Opinion in Immunology 2007, 19:
652-657
I L -4
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
7575
T h1I L - 1 2I F N -
T h2I L - 4IL - 5
A S T HM A
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T he interleukins are able to rebalance the Immune S ystem in
A llergy
7676
T h1I L - 1 2IN F -
T h2I L - 4IL - 5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Healing from A sthma
7777
E ffects of low dose cytokines in treatment of inflammatory
pathologies: use in an animal model of allergic asthma
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
in c o o p e r a t i o n wit h:
E XP E R I M E N T A L P R O T O C O L
D A Y 1
In je c t i o n o f 1 m g o f e g g -a l b u m i n + 5 m g A l ( O H )3i n P BS ( I P )
D A Y 7
In je c t i o n o f 1 m g o f e g g -a l b u m i n + 5 m g A l ( O H )3i n P BS ( I P )
D A Y 1 3
A e r o s o l o f 1 m g o f e g g -a l b u m i n + 5 m g A l ( O H )3i n P BS
f r o m D A Y 1 8 u n t i l D A Y 3 8Blo o d d r a w i n g
T R E A T M E N T WIT H I L -1 2 +I F N - γ
L U C KY M O U S
E
A L L E RG I C
M O U S E
D A Y 2 7In je c t i o n o f 1 m g o f e g g -
a l b u m i n + 5 m g
D A Y 3 05% e g g -
a l b u m i n in P BS 0 ,5. ( A e r o s o l )
D A Y 38Bronchoalveolar
lavage fluid
0
10
20
30
40
50
60
[IL-
4] (
pcg/
ml)
0
20
40
60
80
1 00
[IL-
5] (
pcg/
ml)
1 20
1 40
1 60
1 80
U N T R O VA U N T R O VA
BA L F – after treatment with egg albumin and A l (O H)3
A sthma© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T h2
T h1
Legend
• 1 - U ntr=healthy mouse• 2- O VA =allergic mouse
P rotocol G roups to test efficacy of treatment with 2 anti- allergic
interleukins in combination (I L -1 2+I F N - γ) in the allergic mouse
Legend• 1 - U ntr- - healthy mouse• 2- O VA - - allergic mouse• 3- O VA +A L L O - - I L - 1 2+I F N - γin pharmacological concentration• 4- O VA +4CH- - I L - 1 2+I F N - γ in physiological concentration (4CH) dilution and dynamized• 5- O VA +4CHn- - I L - 1 2+I F N - γ in physiological concentration (4CH) dilution © D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
10
20
30
40
50
60
70
IL-4
pg/
ml
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
20
40
60
80
100
120
140
160
180
IL-5
pg/
ml
L evel of I L - 4 and I L - 5 in mice sera
on day 7th of treatment
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 2 3 4 5
1 2 3 4 5
T reatment plan of allergic mouse with the 2 anti- allergic interleukines in association
(IL - 1 2+IF N - γ)
Legenda• 1 - U ntr=healthy mouse• 2- O VA =allergic mouse• 3- O VA +A L L O =IL - 1 2+IF N - γ in pharmacological concentration• 4- O VA +4CH=IL - 1 2+IF N - γ in physiological concentration (4CH) diluted and dinamized• 5- O VA +4CHn=IL - 1 2+IF N - γ in physiological concentration (4CH) only diluted but not dinamized
L evels of I L - 4
L evels of I L - 5
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
500
1000
1500
2000
2500
IL-1
2 pg
/ml
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
1000
2000
3000
4000
5000
6000
IFN
gam
ma
pg/m
l
L evel of I L - 1 2 and IN F - γin mice sera
on day 7th of treatment
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 2 3 4 5
1 2 3 4 5
T reatment plan of allergic mouse with the 2 anti- allergic interleukines in association
(IL - 1 2+IF N - γ)
Legenda
• 1 - U ntr=healthy mouse• 2- O VA =allergic mouse• 3- O VA +A L L O =IL - 1 2+IF N - γ in pharmacological concentration• 4- O VA +4CH=IL - 1 2+IF N - γ in physiological concentration (4CH) diluted and dinamized• 5- O VA +4CHn=IL - 1 2+IF N - γ in physiological concentration (4CH) only diluted but not dinamized
L evels of I L - 1 2
L evel of I F N - γ
p gp gf gf g
U nit of measurement……the mistery… that is not a
mistery
4CH
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
we give… …we detect in the blood
U N T R E A T E D 0
O V A =C O N T R O L ( A L L E R G I C M O U S E ) 2 0 , 1 88±0 , 6 1 3
OVA + A L L O ( P H A R M A C O L O G I C A L T R E A T M E N T ) 0
OVA + 4 C H ( 4 C H S K A - A C T IVIT E D T R E A T M E N T ) 0
O V A +4 C H n ( 4 C H n o t - SKA -A C T I V I T E D T R E A T M E N T ) 19,567±0 , 6 85
O V A +3 0 C H ( 3 0 C H SKA - A C T I V I T E D T R E A T M E N T ) 2 0 ,788±0 , 4 1 6
Number of cells expressed in cells/BALF (x1 04)
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
E osinophil numbers in mouse BA L F
(bronchoalveolar lavage fluid) on day 20 of treatment
IL-12
0,00
5,00
10,00
15,00
20,00
25,00
30,00
Untr OVA+100ng/die OVA+4CH din
[IL-1
2] (p
g/m
l)
05
101520253035404550
Untr OVA+100ng/die OVA+4CH din
[IFN
gam
ma]
(pg/
ml)
IFN-g
S afety of clinical use of S KA treated low doses of interleukines
P reliminary datas
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
PRM
ANTI AG ING THERAPIES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
86
Ivo BIANCH I M.D. ©
E L D E R L Y P e o p l e
L o w R e a c t i v i t y
Ce l lS t i m u l a t i o n G U N A Ce l l
T i s s u eS t i m u l a t i o n G U N A M a t r i x
H o r m o n a lS t i m u l a t i o n
G U N A F e m a l e / M a l e
Im m u n e S t i m u l a t i o n Cit o m i x
H i g h L e v e l o fIn t o x i c a t i o n D r a i n a g e
G e n e r i c
S p e c i f i c
H i g h L e v e l o fIn f l a m m a t i o n
A n t i In f l a m m a t i o n
G U N A F l a m
IL - 1 0
• G U N A - F E M / M A L E : 2 0 d r o p s t w i c e a d a y fo r 2 - 4 m o n t h s
+G U N A - F L A M : 2 0 d r o p s t w i c e a d a yfo r 2 - 4 m o n t h s
• M E L A T O N I N 4 C H : 2 0 d r o p s a t e v e n i n ge v e r y d a y fo r 2 - 4 m o n t h s
+• I G F 1 4 CH : 2 0 d r o p s a t e v e n i n g e v e r y d a y fo r2 - 4 m o n t h s (anti-neoplastic and anti-oxidant action)
• I L 2 4 CH : 2 0 d r o p st w i c e a d a y fo r 2 - 4 m o n t h s (it is the “amti-aginginterleukine)
• CE R E B R U M CO M P . : 1 a m p o u l e v r y 2 d a y s fo r 2 - 4 m o n t h s (elderly people)
• G U N A -G E R I A T R I CS : 2 0 d r o p s t w i c e a d a y f o r 2 - 4 m o n t h s
A N T I A G I N G G E N E R A L S T R A T E G Y
• G U N A - M A T R I X: 2 0 d r o p s t w i c e a d a y fo r 2 - 4 m o n t h s
+• G U N A - CE L L : 2 0 d r o p s t w i c e a d a y fo r 2 - 4 m o n t h s
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
88
T r o p h i ce f f e c t
A n t i a g i n g
Ca t a b o l i ce f f e c t
A n t i c a n c e r
M e l a t o n i n
T 3
S o m a t o s t a t i n
IG F - 1
D H E A
G H
I n a n i m a l s l o n g l i f e i s c o r r e l a t e d w i t h :
◦H i g h l e v e l s o f : I G F - 1M e l a t o n i n
Ma t r i x liqu i f i c a t i
o n a n d dr a i n a ge
Ac t i o n a ga i n st t o xi n im p r e gn a t i o
n Lym p ha t i
c dr a i n a ge
•S t i m u la t i o n o f m i t o c ho n dr i a l
e n e r gy p r o du c t i o n . *
•Ma t r i x a c i di f i c a t i o n (p r o m o t i n g
c o n n e c t i ve t i ssu e r e a c t i vi t y). **
•Ac. D-L malicum 6X*•Natrium oxal. 6X*
•Natrium pyruv. 6X*•NADID 6X*
•Trychinoil 6X*•Vit. C 2X*
•Ac. L(+) lacticum3X**•D e a c t i va t i o n (thr o u gh in f la m m a t i o n ) a n d n e u t r a li za t i o n o f t he im p r e gn a t e d t o xi n s*.
•S yn e r gi st i c a c t i o n wit h Fu c u s a n d t hyr o i d ho r m o n e a c t i va t i n g the sym p a t he t i c o t o n i c n e r vo u s syste m **.
•Pyrogenium 12X*•Fucus 3X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**
•In a c t i ve t o xi n s m o bi li ze d t o wa r ds t he lym p ha t i c c i r c le f o r dr a i n a ge
•Lymphatic vessel 6X
•Ma t r i x hydr o lysi s*
•Ac t i o n a ga i n st t he c o n st i t u t i o n a l t e n de n c y t o im p r e gn a t i o n o f t he m a t r i x wit h t o xi n s a n d t o t he de ve lo p m e n t o f Dysmetabolic Mesenchymopathy (psychcosis).**
•Ma t r i x
•Hyaluronidase 6X*•Thuja 6/8/12/30/200X**
•Natrium sulfuricum 6/8/12/30/200X **•Prolactine 6X***
•DHEA 6X***•In c r e a se o f Fu n da m e n t a l S u bst a n c e kin e t i c s (p r o t e i n hydr o lysi s, hyp e r -i o n i c i t y, hist a m i n i c a c t i vi t y, in c r e a se d t e m p e r a t u r e ) a n d m a t r i x t u r n o ve r r a t e . *
•S ym p a t he t i c o t o n i c
•IL 6 4C*•DHEA 6X*
•Pyrogenium 12X*•Conjunctive Tissue 6X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**•Prolactine 6X***
G UNA-MATRIX
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
91
• Mo du la t i o n o f t he n e u r o ge n i c p ha se o f in f la m m a t i o n *.
• S e n si t i za t i o n o f the be t a -e n do r p hi n p e r i p he r a l r e c e p t o r s**.
• RES st i m u la t i o n a n d hin dr a n c e t o t he p o ssi ble se p t i c p r o gr e ssi o n o f the in f la m m a t o r y p r o c e ss.
The 3 p i lla r s… i n a dr u g
G UNA-FLAM
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ac o n i t u m *Be lla do n n a *
Fe r r u m p ho sp ho r i c u m *Ap i s*
Br yo n i a *Pyr o ge n i u m *Phyt o la c c a *
Na t r i u m p yr u vi c u m *Ac i du m c i t r i c u m *
Cu -glu c o n a t e *An t i IL 1-a lf a **TG F 1 be t a ***
IL 10***
• Mo du la t i o n o f the n e u r o ge n i c , va sa l e xu da t i ve p ha se s o f the in f la m m a t o r y p r o c e ss*.
• Hin dr a n c e t o the in f la m m a t i o n st a r t p o i n t **.
• Po t e n t i a t i o n o f t he im m u n o lo gi c a n t i -in f la m m a t o r y a c t i vi t y ha vi n g Th2-Th3 p o la r i t y***.
Ac o n i t u m *Be t a -e n do r p hi n **
He p a r su lf u r i sPyr o ge n i u m
Fe r r u m p ho sp ho r i c u m
Me la t o n i n 4CHyp o p hysi s p o r c i n e 200X
Pin e a l G la n d 6XCo n ju n c t i ve t i ssu e 12X
• Re gu la t i o n o f t he e xt r a c e llu la r m a t r i x fu n c t i o n t hr o u gh t he m o du la t i o n o f t he hyp o p hysa r y ho r m o n s a c t i o n a n d the p i n e a l gla n d st i m u la t i o n .
G UNA CELL
Vit a m i n s
In c r e a se o f e n e r ge t i c m e t a bo li sm .
Co e n zym e a c t i vi t y p e r f o r m i n g c a t a lyt i c a c t i o n o n c e ll f u n c t i o n s.
Ca t a lyt i c a c t i o n o n e n zym e f u n c t i o n s.
• Ca r r i e r a c t i o n *.
• Re p r o gr a m m i n g o f c e ll f u n c t i o n **.
• 2n d f u n c t i o n m e sse n ge r ***.
-lip o i c -a c . 3X
S u c c i n i c . a c . 3X
Fu m a r i c . a c . 3X
Me t hyglyo xa l 10X
Vit . EVi t . C
Vit . B1, B2, B3, B5, B6, B9, B12
Co lc hi c u m 6/12/30X Co n i u m 6/12/30X
Po do p hyllu m 6/12/30XMe t hyglyo xa l 10X
An t i -de ge n e r a t i ve a n d a n t i -a gi n g a c t i o n .
Ac . -L-c a r n i t i n e * 2X D NA** 6X RNA** 6X
Co lli n so n i a 2X*** c AMP 6X*** Mn -glu c . 3X
Mn -p ho sp h. 6XMg-p ho sp h. 3X
P 4XCa -glu c . 3X
Fe f u m a r . 3XS 3X
S e 3XCu su lp h. 3XZn -glu c . 3X
K-a sp a r t . 3X
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
93
D6D3
S u i s -O r g a n s
10 pg
NT3 NT4 Melatonin
H o r m o n e sN e u r o t r o p h i n s
Plumbummetallicum
Hepar
Lobofrontalis
Glandulasuprarenalis
HypothalamusBarytacarbonica
H o m e o p a t h i cR e m e d i e s
Phenilalanine
Thyrosine
Oxitocine
TRH
LH-RH
ACTH AcidumDL-malicum
Catalysts
Acidumpyruvicum
H o r m o n e s
BDNF
Parabenzochinon
Baryumoxalsuccinicum
Arnica
IGF-1
A minoacids
H e r b a l s(A r n i c a
m o n t a n a )
H e r b a l s(A r n i c a
m o n t a n a )Ca t a l ys ts a n d
a m i n o ac i d s
Ca t a l ys ts a n d
a m i n o ac i d sG r o w t h
f a c t o r s G r o w t hf a c t o r s
H o r m o n e sH o r m o n e sCo u r t e s y fr o m D r . I Bia n c h i
Co u r t e s y fr o m D r . I Bia n c h i
M e l a t o n i nIn s u l i nG r o w i nF a c t o r
A CT H
Co u r t e s y fr o m D r . I Bia n c h i
O x i t o c i n e T R H L H - R H
Co u r t e s y fr o m D r . I Bia n c h i
• Cir c u l a t i n g m e l a t o n i n d e c r e a s e s w i t h a g e a n d in r e c e n t ye a r s m u c h in t e r e s t h a s b e e n f o c u s e d o n i t s im m u n o m o d u l a t o r y e f f e c t .
• M e l a t o n i n s t i m u l a t e s t h e p r o d u c t i o n o f p r o g e n i t o r c e l l s f o r g r a n u l o c yt e s -m a c r o p h a g e s . I t a l s o s t i m u l a t e s t h e p r o d u c t i o n o f N K c e l l s a n d CD 4+ c e l l s a n d in h i b i t s CD 8+ c e l l s .
• T h e p r o d u c t i o n a n d r e l e a s e o f v a r i o u s c yt o k i n e s f r o m N K c e l l s a n d T - h e l p e r lym p h o c yt e s a l s o a r e e n h a n c e d b y m e l a t o n i n .
• M e l a t o n i n p r e s u m a b l y r e g u l a t e s im m u n e f u n c t i o n b y a c t i n g o n t h e im m u n e -o p i o i d n e t w o r k , b y a f f e c t i n g G p r o t e i n - c A M P s i g n a l
M e l a t o n i n h a s t h e p o t e n t i a l t h e r a p e u t i c v a l u e t o e n h a n c e im m u n e f u n c t i o n in a g e d in d i v i d u a l s a n d in p a t i e n t s in a n im m u n o c o m p r o m
Co u r t e s y fr o m D r . I Bia n c h i
Insulin- like growth factors ( I G F s ) a r e p o l i p e p t i d e s w i t h h i g h s e qu e n c e s i m i l a r i t y t o in s u l i n
IG F - 1 i s m a i n l y s e c r e t e d b y t h e l i v e r a s a r e s u l t o f s t i m u l a t i o n b y G H .
IG F - 1 i s im p o r t a n t f o r b o t h t h e r e g u l a t i o n o f n o r m a l p h ys i o l o g y, a s w e l l a s a n u m b e r o f p a t h o l o g i c a l s t a t e s , in c l u d i n g c a n c e r
IG F a x i s h a s b e e n s h o w n t o p l a y r o l e s in t h e p r o m o t i o n o f c e l l p r o l i f e r a t i o n a n d in h i b i t i o n o f a p o p t o s i s
F a c t o r s t h a t a r e k n o w n t o c a u s e v a r i a t i o n in t h e le v e l s IG F - 1 in t h e c i r c u l a t i o n in c l u d e a n in d i v i d u a l s
Co u r t e s y fr o m D r . I Bia n c h i
I t w a s d e m o n s t r a t e d t h a t a d m i n i s t r a t i o n o f A CT H l e d t o f a c i l i t a t i o n o f l e a r n i n g a n d s t r e n g t h e n i n g o f m e m o r y p r o c e s s e s ( c o n d i t i o n e d r e f l e x t r a c e s ). A CT H p r o m o t e d s t r e n g t h e n i n g o f m o v e m e n t , o r i e n t a t i o n a l - i n v e s t i g a t i v e , a n d in t e r s i g n a l a c t i v i t i e s , p r o d u c e d h yp e r a l g e s i a , a n d b l o c k e d t h e e f f e c t s o f n a l o x o n e
A CT H i s i n v o l v e d in m o t i v a t i o n , Co u r t e s y fr o m D r . I Bia n c h i
O x yt o c i n i s a m a m m a l i a n h o r m o n e t h a t a l s o a c t s a s a n e u r o t r a n s m i t t e r in t h e b r a i n .
O x yt o c i n i s r e l e a s e d d u r i n g o r g a s m in b o t h s e x e s .
I n t h e b r a i n , o x yt o c i n i s in v o l v e d in s o c i a l r e c o g n i t i o n a n d b o n d i n g , a n d m i g h t b e in v o l v e d in t h e f o r m a t i o n o f t r u s t b e t w e e n p e o p l e , i n g e n e r o s i t y a n d in t h e r e d u c t i o n o f f e a r
Ca n im p a i r m e m o r y r e t r i e v a l in c e r t a i n a v e r s i v e m e m o r y t a s k s .
Co u r t e s y fr o m D r . I Bia n c h i
T h e b r a i n t r i p e p t i d e t h yr o t r o p i n - r e l e a s i n g h o r m o n e ( T R H ) h a s b e e n d e m o n s t r a t e d t o f a c i l i t a t e c h o l i n e r g i c n e u r o t r a n s m i s s i o n .
T R H m a r k e d l y a t t e n u a t e d s c o p o l a m i n e - i n d u c e d im p a i r m e n t o f s o m e m e a s u r e s o f m e m o r y, m o s t n o t a b l y o n a s e l e c t i v e r e m i n d i n g t a s k .
Cognitive study suggest a facilitatory role for T R H in human memory processes.
S cientific studies suggest that stimulation of T R H may be useful for
Co u r t e s y fr o m D r . I Bia n c h i
N e u r o t r o p h i c f a c t o r s a r e e n d o g e n o u s p r o t e i n s t h a t a l t e r t h e s u r v i v a l , d e v e l o p m e n t , m a i n t e n a n c e , a n d d i f f e r e n t i a t i o n o f n e u r o n s .
E v i d e n c e h a s in d i c a t e d t h a t n e u r o t r o p h i c f a c t o r s m a y b e im p l i c a t e d in t h e n o r m a l f u n c t i o n a l a c t i v i t y o f n e r v e c e l l s .
T h e s e m o l e c u l e s a r e g e n e r a l l y s m a l l , s o l u b l e p r o t e i n s w i t h
Co u r t e s y fr o m D r . I Bia n c h i
N erve G rowth F actor (N G F ) T h e f i r s t k n o w n n e u r o t r o p h i n , a c t s p r e d o m i n a n t l y o n s ym p a t h e t i c a n d s e n s o r y n e u r o n s .
Brain D erived N eurotrophic F actor (BD N F ) S u p p o r t s m o t o n e u r o n d e v e l o p m e n t a n d s u r v i v a l in a n i m a l s a n d p r e v e n t s n a t u r a l l y o c c u r r i n g d e a t h
N eurotrophin 3 (N T - 3) N T - 3 is r e l a t e d t o N G F a n d h a s h o m o l o g y w i t h i t . I t i s f o u n d in m o t o r n e u r o n s , s ym p a t h e t i c n e u r o n s a n d s o m e p e r i p h e r a l s e n s o r y
Co u r t e s y fr o m D r . I Bia n c h i
• A c t i n g o n c e r t a i n CN S n e u r o n s a n d o n t h e p e r i p h e r a l n e r v o u s s ys t e m
• H e l p s t o s u p p o r t t h e s u r v i v a l o f e x i s t i n g n e u r o n s a n d e n c o u r a g e t h e g r o w t h a n d d i f f e r e n t i a t i o n o f n e w n e u r o n s a n d s yn a p s e s
• A c t i v e in t h e H yp p o c a m p u s , Co r t e x , Ba s a l F o r e b r a i n a r e a s v i t a l t o le a r n i n g , m e m o r y, a n d h i g h e r t h i n k i n g .
• A l t h o u g h t h e v a s t m a jo r i t y o f n e u r o n s in t h e b r a i n a r e f o r m e d p r e n a t a l l y, p a r t s o f t h e a d u l t b r a i n r e t a i n t h e a b i l i t y t o g r o w n e w n e u r o n s f r o m n e u r a l s t e m
Co u r t e s y fr o m D r . I Bia n c h i
BD N F is o n e o f t h e m o s t a c t i v e n e u r o t r o p h i n s . M i c e b o r n w i t h o u t t h e a b i l i t y t o m a k e BD N F s u f f e r d e v e l o p m e n t a l d e f e c t s in t h e b r a i n a n d s e n s o r y n e r v o u s s ys t e m , a n d u s u a l l y d i e s o o n a f t e r b i r t h , s u g g e s t i n g t h a t BD N F p l a ys a n im p o r t a n t r o l e in n o r m a l n e u r a l d e v e l o p m e n t
BD N F is a c t u a l l y f o u n d n o t o n l y in t h e b r a i n b u t a l s o in a r a n g e o f t i s s u e a n d c e l l t yp e s : R e t i n a , M o t o r n e u r o n s , Kid n e ys a n d P r o s t a t e .
V a r i o u s s t u d i e s h a v e s h o w n p o s s i b l e l i n k s b e t w e e n lo w le v e l s o f BD N F a n d c o n d i t i o n s s u c h a s : D e p r e s s i o n , S c h i zo f r e n i a ,
Co u r t e s y fr o m D r . I Bia n c h i
N eurotrophin- 3 (N T - 3) s u p p o r t s t h e s u r v i v a l a n d d i f f e r e n t i a t i o n o f n e u r o n e s in t h e c e n t r a l a n d p e r i p h e r a l n e r v o u s s ys t e m s t h r o u g h a n u m b e r o f m e c h a n i s m s t h a t o c c u r in a m a t t e r o f h o u r s o r d a ys . N T - 3 m a y a l s o h a v e a m o r e r a p i d m o d e o f a c t i o n t h a t in f l u e n c e s s yn a p t i c a c t i v i t y in m a t u r e n e u r o n e s . N T - 3 , h a v e b e e n im p l i c a t e d in t h e r e g u l a t i o n o f s yn a p t i c t r a n s m i s s i o n a n d p l a s t i c i t y.
Co u r t e s y fr o m D r . I Bia n c h i
I n c r e a s i n g a m o u n t s o f e v i d e n c e in d i c a t e t h a t i n f l a m m a t o r y p r o c e s s e s a r e in v o l v e d in t h e n e u r o t o x i c i t y o f A D . A c e n t r a l e v e n t in t h e s e p r o c e s s e s a p p e a r s t o b e t h e a c t i v a t i o n o f m i c r o g l i a b y a v a r i e t y o f f a c t o r s , in c l u d i n g b a m yl o i d a n d p r o i n f l a m m a t o r y c yt o k i n e s .
A c t i v a t e d m i c r o g l i a in t u r n r e l e a s e p r o i n f l a m m a t o r y c yt o k i n e s , s u c h a s I L - 1 - b, I L - 6 , a n d T N F - a, t h a t m a y le a d t o n e u r o n a l d e a t h a n d d ys f u n c t i o n b y a v a r i e t y o f m e c h a n i s m s , in c l u d i n g ◦ e n h a n c e m e n t o f g l u t a m a t e - i n d u c e d
e x c i t o t o x i c i t y[
◦ in h i b i t i o n o f lo n g - t e r m p o t e n t i a t i o n , w h i c h l i m i t s f u n c t i o n a l p l a s t i c i t y a f t e r n e u r o n a l in ju r y[
Co u r t e s y fr o m D r . I Bia n c h i
D E M E N T I A
A l zh e i m e r ’s D i s e a s e s
U p r e g u l a t e d .:IL - 6
IL - 1 0T N F
D o w n r e g u l a t e d.: IL - 2
V a s c u l a rD e m e n t i a
U p r e g u l a t e d .:IL - 6
IL - 1 0IL - 1 b
D o w n r e g u l a t e d.: IL - 2
Co u r t e s y fr o m D r . I Bia n c h i
T h yr o x i n e F e n i l a l a n i l n e
Co u r t e s y fr o m D r . I Bia n c h i
N o n e s s e n t i a l a m i n o a c i d s yn t h e s i ze d in t h e b o d y f r o m p h e n yl a l a n i n e . A s a b u i l d i n g b l o c k f o r s e v e r a l im p o r t a n t b r a i n c h e m i c a l s , t yr o s i n e is n e e d e d t o m a k e e p i n e p h r i n e , n o r e p i n e p h r i n e , s e r o t o n i n , a n d d o p a m i n e , a l l o f w h i c h w o r k t o r e g u l a t e m o o d .
D e f i c i e n c i e s in t h i s a m i n o a c i d is a s s o c i a t e d w i t h d e p r e s s i o n .
T yr o s i n e a l s o a i d s in t h e p r o d u c t i o n o f m e l a n i n a n d in t h e f u n c t i o n o f t h e a d r e n a l , t h yr o i d , a n d p i t u i t a r y g l a n d s . T yr o s i n e is a l s o in v o l v e d in t h e s yn t h e s i s o f e n k e p h a l i n s , s u b s t a n c e s t h a t h a v e p a i n - r e l i e v i n g e f f e c t s in t h e b o d y.
L o w le v e l s o f t yr o s i n e h a v e b e e n a s s o c i a t e d w i t h lo w b l o o d p r e s s u r e , lo w b o d y t e m p e r a t u r e , a n d a n u n d e r a c t i v e t h yr o i d . Be c a u s e t yr o s i n e b i n d s u n s t a b l e m o l e c u l e s ( c a l l e d
Co u r t e s y fr o m D r . I Bia n c h i
H e p a r s u i s• S u p p o r t o f D i g e s t i v e a n d D e t o x i c a t o r y
F u n c t i o n s
S u p r a r e n a l s u i s• O p p o s i n g A g e a n d S t r e s s R e l a t e d
E n d o c r i n e d i s f u n c t i o n s
H yp o t h a l a m u s s u i s• R e s e t t i n g o f b i o l o g i c a l c l o c k
L o b u s f r o n t a l i s s u i s• A n t a g o n i zi n g Co g n i t i v e d e t e r i o r a t i o n
Co u r t e s y fr o m D r . I Bia n c h i
A p p l i c a t i o n o f
c yt o k i n e s m o d e l i n A u t o i m m u n e
D i s e a s e s a n d M u s c l e - S k e l e t i c a l P a i n M a n a g e m e n t
A p p l i c a t i o n o f a n t a g o n o s t i c
l o w d o s e S KA -a c t i v e t e d
c yt o k i n e s m o d e l i n A u t o i m m u n e
D i s e a s e s a n d M u s c l e - S k e l e t i c a l P a i n M a n a g e m e n t
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 1 61 1 6
I nflammationCytokines
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
I N F L A M M A T I O N
A N T I - I nflammationCytokines
I L - 1T N F - α
6
• I L - 1• T N F - α• I L - 6
A nti- I L -
1 0
• A nti- I L -• I L - 4• I L - 1 0
Interleukin 1 (I L - 1 ) cytokine secreted by macrophages, monocytes, dendritic cells, fibroblasts and endothelial cells• I L - 1 support inflammatoryprocesses
• Stimulates prostaglandinsproduction
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
INTERLEUKINE-1 (α; ß)
I L - 1
IN F L A M M A T I O NS YN O VI A L P A N N U S
F O R M A T I O N
CA R T I L A G E BR E A KD O WN S
BO N E R E S O R P T I O N
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
IL-1 (α; ß) ACTION MECHANISM
I L - 1 (α; ß) a c t i v a t e :1 . cyclooxygenase type 2(CO X2)2.prostaglandin E 2 (P G E 2)3.nitric oxide (N O )
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
CONVENTIONAL DRUGS TO STOP INTERLEUKINE-1 EFFECTS
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
N S A ID s
CO R TI S O N
A S A
- - -CO X2 P G E 2 N O
Low dose SKA-actived Antibody AntiInterleukins -1 (α and β) in Pain
Management
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A nti I L - 1
I L-1
CO X2
P GE 2
N O
-BL O CK
A ntiI n t e r l e u k i n s - 1 (α; ß) act a s N S A I D s (A ), cortisone (B) and, in part, as salicylates (C), w i t h o u t t h e n e g a t i v e s i d e e f f e c t s c a u s e d
T HE R A P E U T I C A P P R O A CH WIT HL O W D O S E S .K.A . A N T I BO D Y A N T I I L - 1 , I L - 4 & I L - 1 0 IN
M U S CL E - S KE L E T A L P A I N M A N A G E M E N T
• A nti I L - 1 4CH D ecrease of acute inflammation.
• I L - 1 0 4CH D ecrease of chronic inflammation.
• I L - 4 4CH Control of autoimmune © D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• Cytokines are effective
• However pharmacological doses is plagued with severe adverse effects
U nless…1. Marinaro, M. et al. 1999. Use of intransal IL-12 to target predominantly
Th1 responses to nasal and Th2 resposnses to oral vaccines given with cholera toxin. J. Immunol. 162(1): 114-121
2. Mariinaro, M. et al. 1997. Oral but not parenteral interleukin IL-12 redirects T helper 2 (Th2)-type resposnses to an orola vaccine without
altering mucosal IgA responses. J. Exp. Med. 185(3): 415-4273. Lee, S. Y. et al. 2001. Oral administration of IL-12 suppresses
anaphylatctic reactions in a murine model of peanut hypersensitivity. Clin. Immunol. 101(2): 220-228
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
END ORPHIN
En do r p hi n s a r e o r g a n i c c he mi c a l s ubs t a n c e s p r o duc e d by t he CNS, ha vi n g a n t i p a i n a n d p hys i o l o g i c a l c ha r a c t e r i s t i c s s imi l a r t o t ho s e o f morphine a n d opium – ho we ve r t he y ha ve a wide r r a n g e
En do r p hi n s , l i ke a n umbe r o f mo r p hi n i c o r i g i n a l ka l o i ds , c a n c a us e s t a t e s o f e up ho r i a a n d s o mn o l e n c e a c c o r di n g t o t he qua n t i t y r e l e a s e d
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
PRM: What is derived from Homeopathy?
The study of the pharmacological effects of homeopathized
PLANT, MINERALS and ANIMAL COMPONENTS on
healthy humans and their usage depending on the principles
of similarity and effect inversion in an ill subject.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 25
• Ac o n i t i n 10-5 M Fi br i lla t i o n
• Ac o n i t i n 10-7 M Br a dyc a r di a
• Ac o n i t i n 10-18 M No e ffe c to n he a l t hy he a r t
Ryt hm
A conitin experimentation Pennec, J.P., Aubin, M (1984) – Effect of Aconitum and Veratrum on the isolated and perfused heart of the common eel. Comp. Biochem,
Physiol. 776:367.Diffe r e n t e ffe c t s o f Ac o n i t i n c o n c e n t r a t i o n s o n is o l a t e d a n d p e r fus e d e e l he a r t :
X5
X7
X1 8
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
0
5000
10000
15000
20000
25000
35S
-cp
m/1
00g
SM
PS Co n t r o l
5 mg c o r t i s o n e
0.5 mg c o r t i s o n e
0.0005 mg c o r t i s o n e
0.00005 mg c o r t i s o n e
0.000005 mg c o r t i s o n e
H a us s Exp e r ime n t a t i o n (1968)S T U D I E S O N T HE "N O N S P E CI F I C M E S E N CHYM A L R E A CT I O N " A N D T HE “1
T R A N S I T ZO N E " IN M YO CA R D I A L L E S I O N S A N D A T HE R O S CL E R O S I S W. H . H a u s s , U . G e r l a c h , G . Ju n g e - H ül s i n g , H . T h e m a n n W. Wir t h
A n n a l s o f th e N e w Y o r k A c a d e m y o f S c i e n c e s , V o l u m e 1 56 , E x p e r i m e n t a l "M e t a b o l i c " Ca r d i o p a t h e s a n d th e i r R e l a t i o n s h i p t o H i m a H e a r t D i s e a s e ,
P a g e 20 7- 21 8, Ja n 1 96 9, d o i : 1 0 . 1 1 1 1 / j. 1 749- 6 6 3 2. 1 96 9. t b 1 6 729. xEffe c t s o f va r yi n g g luc o c o r t i c o i d c o n c e n t r a t i o n s o n
me s e n c hyma l s ys t e m t ur n -o ve r
(c o n n e c t i ve t i s s ue bio l o g i c a l a c t i vi t y)
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
High doseS t r yc n
o s N u x
v o m i ca
+ + + +
Increased excitability of parasympathetic fibers
p a r a s ym p a t he t i c f i b e r
a c e t yl c h o l i ne
A c e t yl c h o l i n e r e c e p t o r
P a r i e t a l c e l l o f g a s t r i c m u c o s a
p r o to n
p o mp
+
H Cl ( h yd r o c h l o r ic a c i d )
+
E ffects of high dose S trycnos N ux vomica on acetylcholine receptors of
gastric mucosa parietal cells
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Homeopathic dose
S t r yc n os N u x
v o m i c a
- - --
p r o to n
p o mp
-
-
E ffects of ho meo pa t hic do s e S trycnos N ux vomica on acetylcholine receptors of gastric mucosa parietal cells
D ecreased excitability of parasympathetic fiber
p a r a s ym p a t he t i c f i b e r
A c e t yl c h o l in e
A c e t yl c h o l i n e r e c e p t o r
P a r i e t a l c e l l o f g a s t r i c m u c o s a
H Cl ( h yd r o c h l o r ic a c i d )
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• A R N I CA (Arnica montana)• A CO N I T U M (Aconitum napellus)• R HU S T O X. (Rhus toxicodendron)• CIM I CI F U G A (Cimicifuga racemosa)• VIO L A O D O R A T A • CA U L O P HYL L U M (Caulophyllum talictroides)• A CI D U M BE N ZO I CU M• L E D U M (Ledum palustre)• CO L O CYN T HI S (Citrullus colocynthis)
Important homeopatic single remedies for P ain M anagement:
• A CI D U M F O R M I CI CU M• G N A P HA L I U M P O L YCE P HA L U M• R HO D O D E N D R O N CHR YS A N T HU M• L A CHE S I S M U T U S• BR YO N I A A L BA• HYP E R I CU M P E R F O R A T U M• BE L L A D O N N A (Atropa belladonna)• CR O T A L U S HO R R I D U S• KA L M I A L A T I F O L I A• E T C.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• Mo du la t i o n o f t he n e u r o ge n i c p ha se o f in f la m m a t i o n *.
• S e n si t i za t i o n o f the be t a -e n do r p hi n p e r i p he r a l r e c e p t o r s**.
• RES (r e t i c u lo e n do t he lia l syste m ) st i m u la t i o n a n d in hi bi t i o n o f the p o ssi ble se p t i c p r o gr e ssi o n o f the in f la m m a t o r y p r o c e ss.
Ho m e o p a t hi c a n d Mo le c o la r Bio lo gy
r e m e di e s… in 1 dr u g
G UNA-FLAM
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ac o n i t u m *Be lla do n n a *
Fe r r u m p ho sp ho r i c u m *Ap i s*
Br yo n i a *Pyr o ge n i u m *
Phyt o la c c a *Na t r i u m p yr u vi c u m *
Ac i du m c i t r i c u m *Cu -glu c o n a t e *An t i IL 1-a lf a **TG F 1 be t a ***
IL 10***
• Mo du la t i o n o f the n e u r o ge n i c , va sc u la r e xu da t i ve p ha se s o f t he in f la m m a t o r y p r o c e ss*.
• In hi bi t i o n o f t he in f la m m a t o r y c a sc a de st a r t i n g p o i n t **.
• Po t e n t i a t i o n o f im m u n o lo gi c a n t i -in f la m m a t o r y a c t i vi t y ha vi n g Th2-Th3 p o la r i t y***.
Ac o n i t u m *Be t a -e n do r p hi n **
He p a r su lf u r i sPyr o ge n i u m
Fe r r u m p ho sp ho r i c u m
Me la t o n i n 4CHyp o p hysi s p o r c i n e 200X
Pin e a l G la n d 6XCo n ju n c t i va t i ssu e 12X
• Re gu la t i o n o f ECM (e xt r a c e llu la r m a t r i x) f u n c t i o n t hr o u gh m o du la t i o n o f hyp o p hyse a l ho r m o n e a c t i o n a n d p i n e a l gla n d st i m u la t i o n
S U P P O R T I VE O R A L T HE R A P Y IN
P A I N M A N A G E M E N T
Directions• G U N A - F L A M : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 1 m o n t h
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
MATRIX
MEMBRANE RECEPTORS
VESSELS
THE
CON
NEC
TIVE
TIS
SUE
Mo
rpho
-fun
cti
on
al
unit
y: v
es
se
l-m
atr
ix-m
em
bra
ne
re
ce
pto
r
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ma t r i x liqu i f i c a t i
o n a n d dr a i n a ge
Ac t i o n a ga i n st t o xi n im p r e gn a t i o
n Lym p ha t i
c dr a i n a ge
•S t i m u la t i o n o f m i t o c ho n dr i a l
e n e r gy p r o du c t i o n . *
•Ma t r i x a c i di f i c a t i o n (p r o m o t i n g
c o n n e c t i ve t i ssu e r e a c t i vi t y). **
•S t i m u la t i o n o f m i t o c ho n dr i a l
e n e r gy p r o du c t i o n . *
•Ma t r i x a c i di f i c a t i o n (p r o m o t i n g
c o n n e c t i ve t i ssu e r e a c t i vi t y). **
•Ac. D-L malicum 6X*•Natrium oxal. 6X*
•Natrium pyruv. 6X*•NADID 6X*
•Trychinoil 6X*•Vit. C 2X*
•Ac. L(+) lacticum3X**•D e a c t i va t i o n (thr o u gh in f la m m a t i o n ) a n d n e u t r a li za t i o n o f t he im p r e gn a t e d t o xi n s*.
•S yn e r gi st i c a c t i o n wit h Fu c u s a n d t hyr o i d ho r m o n e a c t i va t i n g the sym p a t he t i c o t o n i c n e r vo u s syste m **.
•D e a c t i va t i o n (thr o u gh in f la m m a t i o n ) a n d n e u t r a li za t i o n o f t he im p r e gn a t e d t o xi n s*.
•S yn e r gi st i c a c t i o n wit h Fu c u s a n d t hyr o i d ho r m o n e a c t i va t i n g the sym p a t he t i c o t o n i c n e r vo u s syste m **.
•Pyrogenium 12X*•Fucus 3X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**
•In a c t i ve t o xi n s m o bi li ze d t o wa r ds t he lym p ha t i c c i r c le f o r dr a i n a ge
•In a c t i ve t o xi n s m o bi li ze d t o wa r ds t he lym p ha t i c c i r c le f o r dr a i n a ge
•Lymphatic vessel 6X
•Ma t r i x hydr o lysi s*
•Ac t i o n a ga i n st t he c o n st i t u t i o n a l t e n de n c y t o im p r e gn a t i o n o f t he m a t r i x wit h t o xi n s a n d t o t he de ve lo p m e n t o f Dysmetabolic Mesenchymopathy (psychcosis).**
•Ma t r i x
•Ma t r i x hydr o lysi s*
•Ac t i o n a ga i n st t he c o n st i t u t i o n a l t e n de n c y t o im p r e gn a t i o n o f t he m a t r i x wit h t o xi n s a n d t o t he de ve lo p m e n t o f Dysmetabolic Mesenchymopathy (psychcosis).**
•Ma t r i x
•Hyaluronidase 6X*•Thuja 6/8/12/30/200X**
•Natrium sulfuricum 6/8/12/30/200X **•Prolactine 6X***
•DHEA 6X***•In c r e a se o f Fu n da m e n t a l S u bst a n c e kin e t i c s (p r o t e i n hydr o lysi s, hyp e r -i o n i c i t y, hist a m i n i c a c t i vi t y, in c r e a se d t e m p e r a t u r e ) a n d m a t r i x t u r n o ve r r a t e . *
•S ym p a t he t i c o t o n i c
•In c r e a se o f Fu n da m e n t a l S u bst a n c e kin e t i c s (p r o t e i n hydr o lysi s, hyp e r -i o n i c i t y, hist a m i n i c a c t i vi t y, in c r e a se d t e m p e r a t u r e ) a n d m a t r i x t u r n o ve r r a t e . *
•S ym p a t he t i c o t o n i c
•IL 6 4C*•DHEA 6X*
•Pyrogenium 12X*•Conjunctive Tissue 6X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**•Prolactine 6X***
G UNA-MATRIX
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 3 4
•S t i m u la t i o n o f Lym p h f lo w wit h st a bi li za t i o n o f ve sse l wa ll t o n e
wit h c o n se qu e n t r e du c t i o n o f t he e xu da t e a n d t he lym p ho e de m a .
•S t i m u la t i o n o f Lym p h f lo w wit h st a bi li za t i o n o f ve sse l wa ll t o n e
wit h c o n se qu e n t r e du c t i o n o f t he e xu da t e a n d t he lym p ho e de m a .
•In hi bi t i o n o f t he p r o li f e r a t i ve
t e n de n c i e s o f t he lym p ho -
e p i t he li a l t i ssu e s
•In hi bi t i o n o f t he p r o li f e r a t i ve
t e n de n c i e s o f t he lym p ho -
e p i t he li a l t i ssu e s
•S t i m u la t i o n o f Hu m o r a l
Im m u n i t y a n d in hi bi t o r y
m o du la t i o n o f t he e xc e ssi ve
c e ll m e di a t e d c o m p e n sa t o r y
r e sp o n se
•S t i m u la t i o n o f Hu m o r a l
Im m u n i t y a n d in hi bi t o r y
m o du la t i o n o f t he e xc e ssi ve
c e ll m e di a t e d c o m p e n sa t o r y
r e sp o n se
•Re du c t i o n o f lo c a l
in f la m m a t i o n o n lym p ho -e p i t he li a l
t i ssu e s.
• Re du c t i o n o f lym p ha t i c sp a sm
du e t o in f la m m a t i o n
wit h r e st o r a t i o n o f t he lym p ha t i c
c i r c u la t i o n .
•Re du c t i o n o f lo c a l
in f la m m a t i o n o n lym p ho -e p i t he li a l
t i ssu e s.
• Re du c t i o n o f lym p ha t i c sp a sm
du e t o in f la m m a t i o n
wit h r e st o r a t i o n o f t he lym p ha t i c
c i r c u la t i o n .
G UNA-LYMPHO
REACTIVATION OF THE
LYMPHATIC
CIRCULATION
HYPERTROPHY AND HYPERPLAS IA OF THE LYMPHATIC
ORG ANS
S TRENG HTENING IMMUNE D EFENCE
ANTI-INFLAMMATORY ACTIVITY ON THE
LYMPHO-EPITHELIAL TIS S UES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Hydr a st i s 1XJu gla n s 3X
G r a p hi t e s 6/12/30/200X
Ma gn e si u m p ho sp ho r i c u
m 6/12/30/200X
Ju gla n s
Ma gn e si u m p ho sp ho r i c u
m 6/12/30/200X
Ju gla n s
Ca le n du la 1XPhyt o la c c a 3X
Ap i s 8XMa gn e si a p ho sp h.
6/12/30/200X
Myo so t i s 3XEqu i se t u m 3XHydr o c o t i le 1XTa r a xa c u m 1X
S a r sa p a r i lla 3XLym p ha t i c ve sse l 6XCa p i lla r y t i sssu e 6X
L-Thyr o xi n 6/12XVe i n p o r c i n e 6X
D -L Ma li c Ac . /Fu m a r i c u m Ac . /Pyr u vi c u m Ac .Tryc hi n o i l/Na t r i u m o xa la c .
1 3 5
D R A I N A G E T HE R A P Y IN P A I N M A N A G E M E N T
Directions
• G U N A - M A T R I X: 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s• G U N A - L YM P HO : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h sA L L T H E A . M . P R O D U CT S CA N BE T A KE N T O G E T H E R ( f o r e x a m p l e p u t t i n g 3 0 - 40 d r o p s o f e a c h m e d i c i n e in 1 l i t r e b o t t l e o f w a t e r . T h e p a t i e n t d r i n k s t h i s b o t t l e d u r i n g t h e w h o l e d a y)
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 3 7
PAIN MANAGEMENT
- LOCAL TH ERAPY -
M ore than 35% of patients suffers from M S K conditions.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain
M anagement
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Give relief to patients in a NATURAL and BIOLOGICAL WAY and WITHOUT SIDE EFFECTS.
G U N A- P O L Y A R T H R I T I SJo i n tp a i n
G U N A-M U S CL EM u s c l ep a i n
G U N A-N E CK
G U N A-S H O U L D E R
G U N A-N E U R A LN e r v ep a i n
G U N A-H I P
G U N A-T H O R A CI C
G U N A-L U M BA R
G U N A-IS CH I A L
G U N A-H A N D FO O T
Chart of area/zone connections
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
E very ampoule contains 1 0 active ingredients; 7 of them are specific for a specific type of pain or parts of the body; 3 of them are specific for pain © D i p a r t i m e n t o
S c i e n t i f i c o G u n a S . p . a .
T HE R A P E U T I C U N I T
1 421 42
I nflammationI nterleukine
I N F L A M M A T I O N
A N T I - I nflammationA ntibody
I L - 1• I L - 1 A nti-I L - 1• A nti-I L - 1
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Interleukin 1 (I L - 1 ) cytokine secreted by macrophages, monocytes, dendritic cells, fibroblasts and endothelial cells.I L - 1 S U P P O R T S I N F L A M M A T O R Y
P R O CE S S E S© D i p a r t i m e n t o
S c i e n t i f i c o G u n a S . p . a .
INTERLEUKINE-1 (α; ß)
IL-1 (α; ß) ACTION MECHANISM
I L - 1 (α; ß) a c t i v a t e s :1 . cyclooxygenase type 2(CO X2)2.prostaglandin E 2 (P G E 2)3.prostaglandin D 2 (P G D 2)4.nitric oxide (N O )
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
I L - 1
IN F L A M M A T I O NS YN O VI A L P A N N U S
F O R M A T I O N
CA R T I L A G E BR E A KD O WN S
BO N E R E S O R P T I O N
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
CONVENTIONAL DRUGS TO STOP INTERLEUKINE-1 EFFECTS
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
N S A ID s
CO R TI S O N
A S A
- - -CO X2 P G E 2/
D 2N O
Low dose SKA-activated Antibody AntiInterleukins -1 (α and β) in Pain
Management
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A nti I L - 1
I L-1
CO X2
P GE 2
N O
-BL O CK
A ntiI n t e r l e u k i n - 1 (α; ß) acts a s N S A I D s , cortisone and, in part, as salicylate , w i t h o u t t h e n e g a t i v e s i d e e f f e c t s c a u s e d b y
β-END ORPHIN
En do r p hi n s a r e o r g a n i c c he mi c a l s ubs t a n c e s p r o duc e d by t he CNS, ha vi n g a n t i p a i n a n d p hys i o l o g i c a l c ha r a c t e r i s t i c s s imi l a r t o t ho s e o f morphine a n d opium – ho we ve r t he y ha ve a wide r r a n g e .
En do r p hi n s , l i ke a n umbe r o f a l ka l o i ds , s uc h a s mo r p hi n , c a n c a us e s t a t e s o f e up ho r i a a n d s l e e p n e s s a c c o r di n g t o t he qua n t i t y r e l e a s e d.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
H E A L T H
P HYS I O L O G I CA L CO N CE N T R A T I O N
1 0- 6
1 0-1 5
4C – X6
Concentration of A nti I L - 1 (α; β) and β- endorphin
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• A R N I CA (Arnica montana)• A CO N I T U M (Aconitum napellus)• R HU S T O X. (Rhus toxicodendron)• CIM I CI F U G A (Cimicifuga racemosa)• VIO L A O D O R A T A • CA U L O P HYL L U M (Caulophyllum talictroides)• A CI D U M BE N ZO I CU M• L E D U M (Ledum palustre)• CO L O CYN T HI S (Citrullus colocynthis)
Important homeopatic single remedies in P .R .M . P ain
M anagement ampoules:• A CI D U M F O R M I CI CU M• G N A P HA L I U M P O L YCE P HA L U M• R HO D O D E N D R O N CHR YS A N T HU M• L A CHE S I S M U T U S• BR YO N I A A L BA• HYP E R I CU M P E R F O R A T U M• BE L L A D O N N A (Atropa belladonna)• CR O T A L U S HO R R I D U S• KA L M I A L A T I F O L I A• E T C.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 52
• S t a n d a r d p r o t o c o l f o r i . m . a d m i n i s t r a t i o n : 1 a m p o u l e 1 - 3 t i m e s a w e e k a c c o r d i n g t o s e v e r i t y a n d c l i n i c a l e v o l u t i o n .
• S t a n d a r d p r o t o c o l a c c o r d i n g t o m e s o t h e r a p e u t i c t e c h n i qu e : 1 - 2 a m p o u l e s p e r t r e a t m e n t : 2 t r e a t m e n t s f o r t h e f i r s t 2 w e e k s , t h e n 1 t r e a t m e n t a w e e k t i l l p a i n r e l i e f ( a v e r a g e 8- 1 0 s e s s i o n s ). Fo r c h r o n i c p a t h o l o g i e s : c o n t i n u e 1 t r e a t m e n t a
P A I N M A N A G E M E N T
T R E A T M E N T P R O T O CO L
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
S U P P O R T I VE O R A L T HE R A P Y IN
P A I N M A N A G E M E N T
Directions• G U N A - F L A M : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• Mo du la t i o n o f t he n e u r o ge n i c p ha se o f in f la m m a t i o n *.
• S e n si t i za t i o n o f the be t a -e n do r p hi n p e r i p he r a l r e c e p t o r s**.
• RES (r e t i c u lo e n do t he lia l syste m ) st i m u la t i o n a n d in hi bi t i o n o f the p o ssi ble se p t i c p r o gr e ssi o n o f the in f la m m a t o r y p r o c e ss.
Ho m e o p a t hi c a n d Mo le c u la r Bio lo gy
r e m e di e s… in 1 sin gle dr u g: G UNA-FLAM
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ac o n i t u m *Be lla do n n a *
Fe r r u m p ho sp ho r i c u m *Ap i s*
Br yo n i a *Pyr o ge n i u m *
Phyt o la c c a *Na t r i u m p yr u vi c u m *
Ac i du m c i t r i c u m *Cu -glu c o n a t e *An t i IL 1-a lf a **TG F 1 be t a ***
IL 10***
• Mo du la t i o n o f the n e u r o ge n i c , va sc u la r e xu da t i ve p ha se s o f t he in f la m m a t o r y p r o c e ss*.
• In hi bi t i o n o f t he in f la m m a t o r y c a sc a de st a r t i n g p o i n t **.
• Po t e n t i a t i o n o f im m u n o lo gi c a n t i -in f la m m a t o r y a c t i vi t y ha vi n g Th2-Th3 p o la r i t y***.
Ac o n i t u m *Be t a -e n do r p hi n **
He p a r su lf u r i sPyr o ge n i u m
Fe r r u m p ho sp ho r i c u m
Me la t o n i n 4CHyp o p hysi s p o r c i n e 200X
Pin e a l G la n d 6XCo n ju n c t i va t i ssu e 12X
• Re gu la t i o n o f ECM (e xt r a c e llu la r m a t r i x) f u n c t i o n t hr o u gh m o du la t i o n o f hyp o p hyse a l ho r m o n e a c t i o n a n d p i n e a l gla n d st i m u la t i o n
D R A I N A G E T HE R A P Y IN P A I N M A N A G E M E N T
Directions• G U N A - M A T R I X: 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s
+• G U N A - L YM P HO : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s
A L L T H E A . M . P R O D U CT S CA N BE T A KE N T O G E T H E R ( f o r e x a m p l e p u t t i n g 3 0 - 40 d r o p s o f e a c h m e d i c i n e in 1 l i t r e ( 3 3 f l o z) b o t t l e o f w a t e r . T h e p a t i e n t d r i n k s t h i s “t h e r a p e u t i c c o c k t a i l ” d u r i n g t h e w h o l e d a y). © D i p a r t i m e n t o
S c i e n t i f i c o G u n a S . p . a .
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 56
• WHE R E : intradermal• HO W M A N Y P O I N T S : 5- 6- 7• HO W M U CH: 0.3- 0.5 ml each injection
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
S YR I N G E S F O R P A I N
M A N A G E M E N T
2,5 ml
5 ml 1 0 ml
20 ml
IN S UL I N
1 3 m m.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
N E E D L E S F O R P A I N M A N A G E M E N T
30 G
L E N G HT
G A U G E
1 59
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
•Be t a -En do r p hi n 4C
•An t i in t e r le u ki n 1 a lp ha 4C
•An t i in t e r le u ki n 1 be t a 4C
•Le dum p a l us t r e 8X•Vis c um a lbum 10X
P.N. E. I. a n t a lgi c
c o r eAn t i -
i n f la m ma t o r y c o r e
Chr o n i c in f la m m a t o
r y p a i n
Ac u t e in f la m m
a t o r y p a i n
•Sa l yc i l i c um a c idum 2X
•Ac o n i t um 6X
•Dro s e r a 8X
•Co l c hi c um a ut umn a l e 10X
•Gua i a c um 10X
Exa m p le o f P. R. M. Pa i n Ma n a ge m e n t a m p o u le :
GUNA®-POLYARTH RITIS
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 0
Cl i n i c a l In di c a t i o n s
GUNA®-NECK
Ne c k p a i n due t o c a r t i l a g e de g e n e r a t i ve c e r vi c a l s p i n e dis o r de r s (c e r vi c a l o s t e o a r t hr o s i s ) Ne c k p a i n due t o c e r vi c a l mus c ul a r t r i g g e r p o i n t s St i ff n e c k s yn dr o me Simp l e n e c k p a i n Whip l a s h Po s t ur a l n e c k a c he Me c ha n i c a l imba l a n c e (fa c e t jo i n t s yn dr o me ) Ce r vi c a l s p i n a l l i g a me n t s yn dr o me Ce r vi c a l s p i n a l n e r ve r o o t p a i n© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 1
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
• Mo dul a t i o n o f IL1 a a n dIL1 b p r o -i n fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n dIL1 b p r o -i n fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Re duc t i o n o f c e r vi c a l r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n :
• Fibr o mya l g i c o r i g i n (Picricum acidum)
• Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Crotalus horr., Nux vomica, Magnesia phosph.)
• Ne vr a l g i c o r i g i n (Magnesia phosph.)An a e s t he t i c o r i g i n :
• Picricum acidum
Re duc t i o n o f c e r vi c a l r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n :
• Fibr o mya l g i c o r i g i n (Picricum acidum)
• Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Crotalus horr., Nux vomica, Magnesia phosph.)
• Ne vr a l g i c o r i g i n (Magnesia phosph.)An a e s t he t i c o r i g i n :
• Picricum acidum
• Bio s t imul a t i o n c a r t i l a g e ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• An t i -de g e n e r a t i ve a c t i o n (Discus intervertebralis)
• Bio s t imul a t i o n c a r t i l a g e ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• An t i -de g e n e r a t i ve a c t i o n (Discus intervertebralis)
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
• Ma g n e s i a p ho s p ho r i c a 12X
•Pic r i c um a c . 8X
• Cro t a l us ho r r i dus 10X
• Nux vo mi c a 10X
• Sil i c e a 4X
• St imul a t i o n o f o s t e o bl a s t s fun c t i o n a n d c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
• St imul a t i o n o f o s t e o bl a s t s fun c t i o n a n d c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
• Ca r t i l a g o s ui s 4X
•In t e r ve r t e br a l dis k, Po r c i n e 4X
An t i -de g e n e r a t ive c o r e 2
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
GUNA®-NECK
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s P.N.E.I.
a n t a l g i c c o r e
H o me o p a t hic a n t a l g i c
c o r e
An t i -in fl a mma t o
ry c o r e
An t i -de g e n e r at i ve c o r e
1
1 6 2
in t o s p e c i fi c a n d s e l e c t e d
lo c a l Ac up un c t ur e Po i n t s
GUNA®-NECK
GV 16
GB 20
BL 10
GV 15
GB 21
GV 14
SI 9
SI 10
GB 21
1 6 3
in t o Tr i g g e r Po i n t s a n d r e fe r r e d p a i n zo n e s
GUNA®-NECK
BL 10
BL 11
TP = Ma i n Tr i g g e r Po i n t s a n d c o r r e l a t e d Ac up un c t ur e p o i n t s
TP
TP
SI 15
TP/SI 14
C 7 C 7
1 6 4
GUNA®-TH ORACICCl i n i c a l
In di c a t i o n sTho r a c i c p a i n due t o c a r t i l a g e de g e n e r a t i ve t ho r a c i c s p i n e dis o r de r s (t ho r a c i c o s t e o a r t hr o s i s ) Tho r a c i c p a i n due t o s c o l i o s i s Tho r a c i c p a i n due t o t ho r a c i c lo n g mus c l e t r i g g e r p o i n t s Pa i n due t o t ho r a c i c s p i n e o s t e o p hyt o s i s Simp l e p o s t e r i o r t ho r a c i c p a i n (t ho r a c i c p a i n s yn dr o me ) Me c ha n i c a l imba l a n c e (c o s t o -ve r t e br a l fa c e t jo i n t s yn dr o me ) Tho r a c i c s p i n a l l i g a me n t s yn dr o me Tho r a c i c s p i n a l n e r ve r o o t p a i n Pa i n fr o m s p i n a l o s t e o p o r o s i s
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 5
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
Re duc t i o n o f the do r s a l ra c hi s p a i n s ymp t o ma t o l o g y o f
diffe r e n t o r i g i n , typ e a n d lo c a l i za t i o n :
Ne ur o -mus c ul a r o r i g i n (Cimicifuga, Chininum
sulph., Conium)
•Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Chelidonium, Spongia)
LOCALIZATION
Do r s a l ra c hi s : dir e c t , a l l ; he p a t i c r e fl e x, Chelidonium.
In t e r c o s t a l p a i n : Spongia
Re duc t i o n o f the do r s a l ra c hi s p a i n s ymp t o ma t o l o g y o f
diffe r e n t o r i g i n , typ e a n d lo c a l i za t i o n :
Ne ur o -mus c ul a r o r i g i n (Cimicifuga, Chininum
sulph., Conium)
•Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Chelidonium, Spongia)
LOCALIZATION
Do r s a l ra c hi s : dir e c t , a l l ; he p a t i c r e fl e x, Chelidonium.
In t e r c o s t a l p a i n : Spongia
•An t i -de g e n e r a t i ve a n d a n t i -n e ur a l g i c a c t i o n•An t i -de g e n e r a t i ve a n d a n t i -n e ur a l g i c a c t i o n
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
•Che l i do n ium ma jus 4X
•Cimi c i fug a ra c e mo s a 4X
•Co n ium ma c ul a t um 6X
•Chin i n um s ul p hur i c um 8X
•Sp o n g i a to s t a 10X
• Ca l c a r e a p ho s p ho r i c a 6X
•Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
•Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
•In t e r ve r t e br a l dis k, Po r c i n e 4X
Co n s t i t ut i o na l c o r e
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
GUNA®-TH ORACIC
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
P.N.E.I. a n t a l g i c
c o r e
H o me o p a t hic a n t a l g i c
c o r e
An t i -in fl a mma t o
ry c o r e
An t i -de g e n e r at i ve c o r e
1 6 6
GUNA®-LUMBARCl i n i c a l
In di c a t i o n s Lumba r p a i n due t o c a r t i l a g e de g e n e r a t i ve lumba r s p i n e dis o r de r s (lumba r a n d lumba r -s a c r a l a r t hr o s i s ) Lumba r ve r t e br a l o s t e o p hyt o s i s Lo w ba c k p a i n due t o mus c ul a r a n d t e n di n o us t r i g g e r p o i n t s Simp l e lumba r p a i n (lo w ba c k s yn dr o me ) We a k lo w ba c k s yn dr o me Po s t ur a l lo w ba c k a c he Lumba r a n d lumba r -s a c r a l me c ha n i c a l imba l a n c e Lumba r a n d lumba r -s a c r a l s p i n a l l i g a me n t s yn dr o me Sa c r o -i l i a c s yn dr o me Sp i n a l lumba r a n d lumba r -s a c r a l n e r ve r o o t p a i n
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 7
•Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o fb–En do r p hi n r e c e p t o r s
•Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o fb–En do r p hi n r e c e p t o r s
•Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
•Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n•An t i -de g e n e r a t i ve
a n d a n t i -n e ur a l g i c a c t i o n
•An t i -de g e n e r a t i ve a n d a n t i -n e ur a l g i c a c t i o n
Re duc t i o n o f the lumba r r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n , typ e
a n d lo c a l i za t i o n :
•Ne ur o -mus c ul a r o r i g i n (Bryonia, Alumina, Ac. Phosphoricum). Ar t i c ul a r o r i g i n (Natrium sulph.)
•Typ e – c r a mp -l i ke p a i n (Ac. phosphoricum); mus c ul a r p a r e s i s p he n o me n a (Alumina)
•Lo c a l i za t i o n –Lumbo s a c r a l r a c hi s : dir e c t , Hamamelis; a bdo mi n a l r e fl e x, Sepia
Re duc t i o n o f the lumba r r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n , typ e
a n d lo c a l i za t i o n :
•Ne ur o -mus c ul a r o r i g i n (Bryonia, Alumina, Ac. Phosphoricum). Ar t i c ul a r o r i g i n (Natrium sulph.)
•Typ e – c r a mp -l i ke p a i n (Ac. phosphoricum); mus c ul a r p a r e s i s p he n o me n a (Alumina)
•Lo c a l i za t i o n –Lumbo s a c r a l r a c hi s : dir e c t , Hamamelis; a bdo mi n a l r e fl e x, Sepia
•Be t a -En do r p hi n 4C
•An t i in t e r l e uki n 1 a l p ha 4C
•An t i in t e r l e uki n 1 be t a 4C
In t e r ve r t e br a l dis k, Po r c i n e 4X
P.N.E.I.
An t a l g i c c o r e
An t i -in fl a mma t o
r y c o r e
An t i -de g e n e r a t i v
e c o r e
H o me o p a t hic a n t a l g i c
c o r e
•Br yo n i a 4X•Se p i a o ffi c i n a l i s 4X
•Pho s p ho r i c um a c . 6X •H a ma me l i s vir g i n i a n a 6X
•Alumi n a 8X•Na t r um s ul p hur i c um 8X
GUNA®-LUMBAR
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 8
GUNA®-ISCH IALCl i n i c a l
In di c a t i o n s
Sc i a t i c a p a i nLumba r -s c i a t i c p a i nNe r ve p a i n in t he lo we r lumba r s p i n e Le g n e r ve p a i n due t o p o s t -s ur g e r y t r e a t me n t o f dis k he r n i a t i o n L4-L5, L5-S1Mo r t o n n e ur o ma © Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 9
P.N.E.I. a n t a l g i c
c o r e
An t i -in fl a mma t o r
y c o r e
Pr ima r y n e ur a l g i c
p a i n
Se c o n da r y n e ur a l g i c
p a i n
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Mo dul a t i o n o f s c i a t i c p a i n by me a n s o f in fl a mma t i o n n e ur o g e n p ha s e in hi bi t i o n (Aconitum and Arsenicum) a n d dir e c t a c t i o n o n the s c i a t i c n e r ve (Gnaphalium)
Mo dul a t i o n o f s c i a t i c p a i n by me a n s o f in fl a mma t i o n n e ur o g e n p ha s e in hi bi t i o n (Aconitum and Arsenicum) a n d dir e c t a c t i o n o n the s c i a t i c n e r ve (Gnaphalium)
• Pa i n mo dul a t i o n by me a n s o f a r e duc t i o n in the p r o g r e s s i o n o f o s t e o c ho n dr o s i s (Cimicifuga), c o xo -fe mo r a l a r t hr o s i s (Rhus tox.),ba c ka c he (Rhus tox).
• Pa i n mo dul a t i o n by me a n s o f a r e duc t i o n in the p r o g r e s s i o n o f o s t e o c ho n dr o s i s (Cimicifuga), c o xo -fe mo r a l a r t hr o s i s (Rhus tox.),ba c ka c he (Rhus tox).
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e un i n 1 be t a 4C
•La c he s i s mutus 8X
•Gn a p ha l i um p o l yc e p ha lum 4X
•Ar s e n i c um a l bum 6X
•Rho do de n dr o n c hr ys a n t um 6X
•Ac o n i t um n a p e l l us 8X
• Cimi c i fug a 4X
• La c he s i s mutus 8X
• Mo dul a t i o n o f a bdo mi n a l wa l l r e fl e xe d s c i a t i c p a i n (Lachesis) a n d il i a c -s a c r a l lumba r p a i n (Cimicifuga)
• Mo dul a t i o n o f a bdo mi n a l wa l l r e fl e xe d s c i a t i c p a i n (Lachesis) a n d il i a c -s a c r a l lumba r p a i n (Cimicifuga)
•Cimi c i fug a 4X
•Rhus to xi c o de n dr o n 4X
Re fl e xe d n e ur a l g i c
p a i n
GUNA®-ISCH IAL
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 70
GUNA®-SH OULDERCl i n i c a l
In di c a t i o n s
Sc a p ul a r -hume r a l p e r i -a r t hr i t i s
Sho ulde r p a i n
Sho ul de r -a r m s yn dr o me
Fr o ze n s ho ul de r
Sho ul de r p a i n due t o dis l o c a t i o n ,
t he r a p e ut i c r e s t
Ep i c o n dyl i t i s
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 71
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n• An t i -de g e n e r a t i ve a n d
c hr o n i c a n t i -i n fl a mma t o r y a c t i o n (Tendon, Porcine)
• An t i -de g e n e r a t i ve a n d c hr o n i c a n t i -i n fl a mma t o r y a c t i o n (Tendon, Porcine)
Re duc t i o n o f s ho ulde r p a i n o f diffe r e n t o r i g i n a n d typ e :
• Ne ur a l g i c o r i g i n (Argentum nitricum, Ferrum phosph., Iris)
• Mus c ul a r o r i g i n (Ranunculus, Sanguinaria)
• Ac ut e p a i n (Ferrum, Iris)
• Chr o n i c p a i n (Argentum nitricum, Ranunculus)
Re duc t i o n o f s ho ulde r p a i n o f diffe r e n t o r i g i n a n d typ e :
• Ne ur a l g i c o r i g i n (Argentum nitricum, Ferrum phosph., Iris)
• Mus c ul a r o r i g i n (Ranunculus, Sanguinaria)
• Ac ut e p a i n (Ferrum, Iris)
• Chr o n i c p a i n (Argentum nitricum, Ranunculus)
•Be t a -En do r p hi n 4C
•An t i in t e r l e uki n 1 a l p ha 4C
•An t i in t e r l e uki n 1 be t a 4C
•Ca r t i l a g o s ui s 4X•Te n do n , Po r c i n e 6X
P.N.E.I. a n t a l g i c
c o r e
An t i -in fl a mma t o
r y c o r e
An t i -de g e n e r at i ve c o r e
H o me o p athi c
a n t a l g i c c o r e
•Arg e n t um n i t r i c um 8X
•Fe r r um p ho s p ho r i c um 8X
•Ir i s ve r s i c o l o r 8X
•Sa n g ui n a r i a c a n a de n s i s 8X
• Ra n un c ulus bulbo s us 10X
GUNA®-SH OULDER
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 72
GUNA®-H ANDFOOTCl i n i c a l
In di c a t i o n sOs t e o a r t hr i t i s o f dig i t s p a i nRhizo a r t hr o s i s o f t he t humb (Fo r e s t i e r dis e a s e )Ar t hr o s i s p a i n due t o ha mme r t o eCa r p a l -t un n e l s yn dr o me De Que r va i n dis e a s eMe t a c a r p a l a n d Me t a t a r s a l p a i nMo r t o n dis e a s e Rhe uma t o i d a r t hr i t i s o f ha n d/fo o tH a n d/Fo o t t e n do n p a i n due t o p r o l o n g e d
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 73
P.N.E.I.
a n t a l g i c c o r e
An t i -in fl a mma t o r
y c o r e
In fl a mma t ory p a i n
De g e n e r at i ve p a i n
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Pa i n mo dul a t i o n by me a n s o f a c ut e in fl a mma t i o n p he n o me n a – va s a l in p a r t i c ul a r –in hi bi t i o n (a r t hr o s i s t yp e )
Pa i n mo dul a t i o n by me a n s o f a c ut e in fl a mma t i o n p he n o me n a – va s a l in p a r t i c ul a r –in hi bi t i o n (a r t hr o s i s t yp e )
• Pa i n mo dul a t i o n by me a n s o f de g e n e r a t i ve p r o c e s s (a r t hr o s i s t yp e ) in hibi t i o n
• Pa i n mo dul a t i o n by me a n s o f de g e n e r a t i ve p r o c e s s (a r t hr o s i s t yp e ) in hibi t i o n
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
•Arn i c a mo n t a n a 4X
•Ca ul o p hi l l um tha l i c t r o ide s 12X
•Le dum p a l us t r e 6X
•Be n zo i c um a c idum 6X
• Pa i n mo dul a t i o n by me a n s o f ur i c a c id c r ys t a l s a c c umul a t i o n in hi bi t i o n (dra i n a g e a c t i o n )
• Pa i n mo dul a t i o n by me a n s o f ur i c a c id c r ys t a l s a c c umul a t i o n in hi bi t i o n (dra i n a g e a c t i o n )
•Vio l a o do r a t a 6X
•Me r c ur ius s o lubi l i s 8X
•Cimi c i fug a ra c e mo s a 10X
Go ut p a i n
GUNA®-H ANDFOOT
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 74
GUNA®-H IPCl i n i c a l
In di c a t i o n s
H i p jo i n t
o s t e o a r t hr o s i sH i p jo i n t c a p s ul e in fl a mma t i o nH i p jo i n t r he uma t o id a r t hr i t i s H i p jo i n t p a i n o f mus c l e o r i g i n H i p jo i n t p a i n o f n e r ve o r i g i n (bur n i n g hip )H i p jo i n t p a i n due t o
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 75
P.N.E.I. a n t a l g i c
c o r e
H o me o p a t hic a n t a l g i c
c o r e
An t i -in fl a mma t o
ry c o r eCo n s t i t ut i on a l c o r e
An t i -de g e n e r a t i v
e c o r e
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Re duc t i o n o f hip p a i n s ymp t o ms o f r he uma t i c o r i g i n
:
• Ca p s ul e (Formicum ac., Argentum)
• Te n do n s a n d li g a me n t s (Rhus tox)
• Ne r ve s (Colocynthis)
• Mus c l e s (Arnica)
Re duc t i o n o f hip p a i n s ymp t o ms o f r he uma t i c o r i g i n
:
• Ca p s ul e (Formicum ac., Argentum)
• Te n do n s a n d li g a me n t s (Rhus tox)
• Ne r ve s (Colocynthis)
• Mus c l e s (Arnica)
• Bio s t imul a t i o n o f c a r t i l a g i n e o us ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• Ne w ve s s e l s de ve l o p me n t s t imul a t i o n (Argentum)
• Bio s t imul a t i o n o f c a r t i l a g i n e o us ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• Ne w ve s s e l s de ve l o p me n t s t imul a t i o n (Argentum)
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
•Arg e n t um me t a l l i c um 6X
•Arn i c a mo n t a n a 8X
•Co l o c yn t hi s 8X
•Fo r mi c um a c . 8X
• Rhus to xi c o de n dr o n 10X
• Ca l c a r e a fluo r i c a 6X
• Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g y
• Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g y
• Ca r t i l a g o s ui s 4X
• Arg e n t um me t a l l i c um 6X
GUNA®-H IP
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 76
GUNA®-POLYARTH RITISCl i n i c a l
In di c a t i o n s Sma l l jo i n t s r he uma t o i d a r t hr i t i s o f ha n d a n d fo o t Co s t o -s t e r n a l s yn dr o me (Tie t ze s yn dr o me ) Chr o n i c p o l ya r t hr i t i s due t o a ut o -immun e dis e a s e s (e .g . Lup us e r yt he ma t o s us s i s t e mi c us ) Br o ke n bo n e s yn dr o me due t o vir a l o r p r o t o zo i c dis e a s e Jo i n t p a i n due t o c a n c e r dis e a s e (c hr o n i c le uke mi a , mo n o c l o n a l blo o d dis e a s e s )
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 77
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
•Be t a -En do r p hi n 4C
•An t i in t e r l e uki n 1 a l p ha 4C
•An t i in t e r l e uki n 1 be t a 4C
•Le dum p a l us t r e 8X•Vis c um a lbum 10X
P.N.E.I. a n t a l g i c
c o r e
An t i -in fl a mma t o
r y c o r e
Chr o n i c in fl a mma t o r y
p a i n
Ac ut e in fl a mma t o r
y p a i n
•Sa l yc i l i c um a c idum 2X
•Ac o n i t um 6X
•Dro s e r a 8X
•Co l c hi c um a ut umn a l e 10X
•Gua i a c um 10X
GUNA®-POLYARTH RITIS
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 78
GUNA®-MUSCLECl i n i c a l
In di c a t i o n sTr i g g e r p o i n t s ma n a g e me n t : a c ut e , s uba c ut e , c hr o n i c
Fibr o mya l g i a s yn dr o me
Re fe r r e d s o ma t i c p a i n a r e a ma n a g e me n t
De r ma t o myo s i t i s© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 79
Ac t i ve in g r e di e n t s : Ar n i c a mo n t a n a 4X H PUS, Co l o c yn t hi s 4X H PUS 4 p a r t s ; Be l l a do n n a 6X H PUS, Li t hi um be n zo i c um 8X H PUS, Mus c l e t i s s ue , Po r c i n e 4C, Pr o c a i n e c hl o r i de 2X 2 p a r t s ; Co l c hi c um a ut umn a l e 6X H PUS, Cup r um s ul p hur i c um 4X H PUS, H yp e r i c um p e r fo r a t um 4X H PUS, In t e r fe r o n g a mma 4C 1 p a r t .
In a c t i ve in g r e di e n t : St e r i l e i s o t o n i c s o dium c hl o r i de s o l ut i o n . © Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 80
Co n t us i ve p a i n
Sp a s t i c o r c r a mp -l i ke
p a i n
Sp r a in
p a i n
•In t e r fe r o n 4C
•Pr o c a i n c hl o r ide 2X
•Mus c l e t i s s ue , Po r c i n e 4C
•Ar n i c a mo n t a n a 4X
•Be l l a do n n a 6X
•Co l o c yn t hi s 4X
•Cup r um s ul p hur i c um 4X
• Co l c hi c um a ut umn a l e 6X
•Lit hi um be n zo i c um 8X
•H yp e r i c um 4X
Mus c ul a r r he uma t i s
m
An t i -de g e n e r a t
ive c o r e
GUNA®-MUSCLE
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 81
GUNA®-NEURALCl i n i c a l
In di c a t i o n s
No n -s p e c i fi c br a c hi a l p a i n Br a c hi a l n e r ve p a i n due t o c e r vi c a l e n t r a p me n t In t e r c o s t a l n e r ve p a i n due t o t ho r a c i c e n t r a p me n t Po s t he r p e t i c n e ur i t i s At yp i c a l fa c i a l n e ur i t i s (Slüde r s yn dr o me , Cha r l i n s yn dr o me ) Tr i g e min a l n e ur i t i s Pa i n o f t he t e mp o r o ma n dibul a r jo i n t (TMJ) Ar n o l d s yn dr o me Ce r vi c a l , t ho r a c i c , lumba r a n d s a c r o l umba r n e r ve r o o t p a i n
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 82
P.N.E.I. a n t a l g ic c o r e
In fl a mma t o ry a e t i o l o g y
Va s c ul a r a e t i o l o g
yDe g e n e r a t i ve
a e t i o l o g y
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Re duc t i o n o f diffe r e n t p e r i p he r a l n e r ve s in fl a mma t i o n
• Re duc t i o n o f diffe r e n t p e r i p he r a l n e r ve s in fl a mma t i o n
Re duc t i o n o f p a i n a n d p a r a e s t he t i c p he n o me n a by me a n s o f hyp e r e me t i c a c t i o n o n n e r ve s
Re duc t i o n o f p a i n a n d p a r a e s t he t i c p he n o me n a by me a n s o f hyp e r e me t i c a c t i o n o n n e r ve s
• Tro p hi c a c t i o n o n r o o t s a n d n e r ve e n di n g s da ma g e d be c a us e o f de g e n e r a t i ve o r le s i o n a r y p he n o me n a
• Tro p hi c a c t i o n o n r o o t s a n d n e r ve e n di n g s da ma g e d be c a us e o f de g e n e r a t i ve o r le s i o n a r y p he n o me n a
• Be t a -En do r p hi n 4C
•Ka lmi a la t i fo l i a 2X
•Fe r r um p ho s p ho r i c um 2X
•Co l o c yn t hi s 4X
•Pa r i s qua dr i fo l i a 6X
•Gn a p ha l i um p o l yc e p ha lum 6X
•Ir i s ve r s i c o l o r 8X
•Ac o n i t um n a p e l l us 8X
•Fo r mi c a rufa 8X
• Ka lmi a la t i fo l i a 2X
• Mo dul a t i o n o f p a r e s i s a n d p a r a l ys i s p he n o me n a
• Mo dul a t i o n o f p a r e s i s a n d p a r a l ys i s p he n o me n a
•Ne ur o t r o p hi n 4 4C
Rhe uma t o id
a e t i o l o g y
GUNA®-NEURAL
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
P .R .M . in P ain M anagement
• Case n° 1L eft homolateral lumbago
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 1L eft homolateral lumbago
T herapy:• G U N A ®- L U M BA R 1 ampoule
+• G U N A ®- M U S CL E 1 ampoule
+ © D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
12
34
7
6
5
L eft homolateral lumbago
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 2T rapezius myalgia
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 2T rapezius myalgia
T herapy:• G U N A ®- M U S CL E 2 ampoule
+• G U N A ®- N E U R A L 1 ampoule
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T rapezius myalgia
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
1
C1
C2
C3C4C5C6C7
65
4
2
3
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 3Whiplash
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 3Whiplash
T herapy:
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 ° T reatment:• G U N A ®- N E CK 1 ampoule
2° T reatment:• G U N A ®-M U S CL E 1 ampoule
+• G U N A ®-N E U R A L 1 ampoule
Whiplash (1 ° treatment)
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
C1
C2
C3C4C5C6C7
3
2
1
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Whiplash(2° treatment)
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
1
C1
C2
C3C4C5C6C7
4
3 2
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 4S capular- humeral peri- artrhitis + 3 trigger points
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 4S capular- humeral peri-artrhitis + 3 trigger points
T herapy:
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 ° T reatment:• G U N A ®- M U S CL E 1 ampoule
+• G U N A ®- N E U R A L 1 ampoule
2° T reatment:• G U N A ®- S HO U L D E R 1 ampoule
+• G U N A ®-P O L YA R T HR I T I S 1 ampoule
S capular- humeral peri- arthritis + 3 trigger points(1 ° treatment)
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
1
C1
C2
C3C4C5C6C7
2
3
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1
2
3
S capular- humeral peri- arthritis + 3 trigger points(2° treatment)
o n t h e a n t e r i o r p a r t o f s h o u l d e r
o n t h e a n t e r i o r p a r t o f s h o u l d e r
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 5A nkle sprain
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 5A nkle sprain
T herapy:
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 ) T reatment of ankle:
• G U N A ®-HA N D F O O T 1 ampoule
2) T reatment of knee:
• G U N A ®- HI P 1 ampoule
A nkle sprain (1 ° treatment)
1
2
3
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A nkle sprain (1 ° treatment)
2
3
14
5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
20 1
IN T E R N A L CA U S E S = M U S CL E E L O N G A T I O N – M U S CU L A R CO N T R A CT I O N - S T R E T CH I N G
T R A U M A TO L O G Y
M U S CU L A R L E S I O N S- M U S CU L A R L E S I O N S
E XT E R N A L CA U S E S = M U S CU L A R CO N T U S I O N
a c u t e p a i n , s w e l l i n g , p a i n f u l t u m e f a c t i o n , ( i n c a s e ) h e m a t o m aT H E R A P Y
- G U N A ®- M U S CL E A M P O U L E S + G U N A ®- N E U R A L A M P O U L E S- G U N A ®- M A T R I X D R O P S- G U N A ®- FL A M D R O P S
:
T H E R A P Y
- G U N A ®- M U S CL E A M P O U L E S + G U N A ®- N E U R A L A M P O U L E S- G U N A ®- FL A M D R O P S- G U N A ®- L Y M P H O D R O P S © Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1
DROPS:
10 dro p s 3 t ime s a da y, 15 min ut e s be fo r e me a l
20 2
T E N D I N I T I S : e d e m a , h e a t , t e n d o n s t i f f n e s s
T R A U M A TO L O G Y
- T E N D I N I T I S80 % in S p o r t M e d i c i ne
• t e n d i n i t i s •t e n d o s yn o vi t i s •t e n d o p e r i os t i t i s• e t c .
T H E R A P Y
1 ) CA L CA N E A N T E N D O N :- G U N A ®-
H A N D / FO O T A M P O U L E S - G U N A ®- M A T R I X D R O P S- G U N A ®- FL A M D R O P S
4) P U BI C P A I N :- G U N A ®- H I P A M P O U L E S
- G U N A ®- FL A M D R O P S- G U N A ®- L Y M P H O D R O P S- G U N A ®- M A T R I X D R O P S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
2
2) BICI P I T A L T E N D I N I T I S :
- G U N A ®- S H O U L D E R A M P . + G U N A- G U N A ®- FL A M D R O P S- G U N A ®- M A T R I X D R O P S
3 ) T E N D O N P A I N FR O M CA S T S :- G U N A ®- H A N D FO O T A M P O U L E S
- G U N A ®- M A T R I X D R O P S- G U N A ®- L Y M P H O D R O P S
20 3
T H E R A P Y
T R A U M A TO L O G Y
- O S T E O BI O S T M D R O P S- G U N A ®- M A T R I X D R O P S- G U N A ®- FL A M D R O P S+ G U N A ®- …. . A M P O U L E S a c c o r d i n g t o t h e a n a t o m i c lo c a l i za t i o n ( e . g . f r a c t u r e o f f e m o r n e c k : G U N A ®- H I P , f r a c t u r e o f h a n d b o n e s : G U N A ®- H A N D FO O T )
D I S L O CA T I O N S- D I S L O CA T I O N S
T H E R A P Y
- FR A CT U R E S
- G U N A ®- FL A M D R O P S- O S T E O BI O S T M D R O P S- G U N A ®- M A T R I X D R O P S- G U N A ®- L Y M P H O D R O P S - in c a s e o f s h o u l d e r d i s l o c a t i o n : a d d G U N A ®- S H O U L D E R A M P O U L E S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
3
20 4
T H E R A P Y
T R A U M A TO L O G Y
P E R I P H E R A L N E R V E L E S I O N S- P E R I P H E R A L N E R V E L E S I O N S
T H E R A P Y
- G U N A ®- N E U R A L A M P O U L E S
- G U N A ®- FL A M D R O P S
- G U N A ®- M A T R I X D R O P S
S Y N D R O M E S D U E T O H Y P E R E XT E N S I O N- S Y N D R O M E S D U E T O H Y P E R E XT E N S I O N
- G U N A ®- N E CK A M P O U L E S
- G U N A ®- T H O R A CI C A M P O U L E S
- G U N A ®- L U M BA R A M P O U L E S
CO M P R E S S I O N S Y N D R O M E SS P R A I N S Y N D R O M E S ( BR A CH I A L P L E XU S )
P O S T O P E R A T I V E P A R E S I S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
4
20 5
20 6
FI BR O M Y AL G I A Fib r o m ya l g i a i s n o t a new s yn d r o m e b u t a r e s u r r e c t i o n o f t h e old“d i a g n o s i s ” f i b r o s i t i s
Fib r o m ya l g i a s yn d r o m e is a v e r y c o m m o n c h r o n i c i l l n e s s w h o s e p a t h o g e n e s i s i s r e p o r t e d t o b e p o o r l y u n d e r s t o o d
Wo m e n a r e m o r e a f f e c t e d t h a n m e n
A l l r a c e s a r e a f f e c t e d
20 7
FI BR O M Y AL G I AD I A G N O S I S : t h e p a t i e n t h a s t o c o n s t a n t l y e x p e r i e n c e t h e s ym p t o m s
f o r m o r e t h a n 3 - 4 m o n t h s a n d h a v e a t le a s t 1 0 T r i g g e r P o i n t sin t o t h e 1 8 c l a s s i c a l s i t e s + d i s t u r b e d s l e e p
Commonly associated conditions: i r r i t a b l e b o w e l s yn d r o m e , m i g r a i n e ,p h yc h i c d e p r e s s i o n , o b s t r u c t i v e s l e e p a p n o e a , g e n e r a l f a t i g u e
S e v e r a l c a u s e s h a v e b e e n id e n t i f i e d : s t r e s s , t e n s i o n , c h i l l , c o n n e c t i v e t i s s u e d i s e a s e s s u c h a s
1 ) o s t e o a r t h r i t i s , n e r v e c o m p r e s s i o n , e n d o c r i n e im b a l a n c e ( e s t r o g e n d e f i c i e n c y, h yp o t h yr o i d i s m )
2) t r a u m a s , r e p e t i t i v e s t r a i n , o v e r u s e3 ) p h ys i c a l - m e n t a l f a t i g u e , a n x i e t yL A B T E S T S A N D X- R A Y : N E G A T I V E FO R S P E CI FI C D I A G N O S I S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
20 8
T H E 1 8 P O I N T S T O T E S T
P O S I T I V E P O I N T : n e e d s t o b e p a i n f u l t o a o f 4Kg / c m 2 p r e s s u r e a p p l i e d b y t h e e x a m i n e r ’s d i g i tP O S I T I V E P O I N T : n e e d s t o b e p a i n f u l w h e n t h e a p p l i e d t h u m b p r e s s u r e i s s u f f i c i e n t t o b l a n c h t h e n a i l -b e d o f t h e d o c t o r ’s t h u m b w h e n h e / s h e p r e s s e s f i r m l y o n
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
20 9
FIBR O M Y A L G I A S Y N D R O M E
L O CA LT H E R A P Y
G U N A ®- M U S CL E +G U N A ®- N E U R A L2 a m p o u l e s (4 m l ) + 1
a m p o u l e (2 m l ) = 6 m lIN T O E A CH T R I G G E R
P O I N T : 0 . 5 m lT R I G G E R P O I N T S IN JE CT E D P E R S E S S I O N : 1 0 - 1 2
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
N U M BE R O F S E S S I O N S : 8 - 1 0
21 0
FIBR O M Y A L G I A S Y N D R O M E
H O M ET H E R A P Y
G U N A ®- FL A M D R O P S 1 5 d r o p s 3 t i m e s a d a y 9a m – 3 p m – 9p m
G U N A ®- M A T R I X D R O P S 1 5 d r o p s 3 t i m e s a d a y 9.3 0 a m – 3 . 3 0 p m – 9.3 0 p m
G U N A ®- S L E E P D R O P S 1 5 – 20 d r o p s a d a y1 0 . 3 0 p m
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
E x a m p le :
D u r a t i o n o f t h e t h e r a p y: 2 m o n t h s